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ABSTRACT 
Phosphocitrate is a potent inhibitor of hydroxyapatite formation with 
demonstrated efficacy in preventing the progression of calcific pathologies in 
animal models. In the present studies, the oral bioavailability of phosphocitrate 
was investigated following administration of the compound by gavage in rats. 
Using a calcergic model, inhibitory action by phosphocitrate was evaluated. 
Accordingly, the formation of small subcutaneous calcific plaques was 
chemically induced. Parameters measured included plaque weight, calcium, 
and phosphorus content. The oral and intraperitoneal routes of administration 
were compared and dose-response relationships established. Phosphocitrate 
was found capable of reducing calcific plaque formation when delivered by 
either route. However reduced bioavailability was apparent following 
administration by gavage revealing the oral route to be approximately 45 times 
less effective on a dose-weight basis than the intraperitoneal route. 
The possibility that poor absorption from the small intestine was 
responsible for the observed differences was explored. Transport studies using 
everted sacs and in situ ligated loops confirmed phosphocitrate absorption. The 
data revealed concentration-dependance and the absence of in vitro intestinal 
transfer at the lowest concentration (1mM) trialled. 
Further studies were necessary to evaluate the extent of phosphocitrate 
absorption from the small intestine. Experiments with radiolabelled 
phosphocitrate and using an in situ perfusion technique with hepatic portal vein 
cannulation yielded additional information. The studies provided conclusive 
evidence that limited amounts of intact phosphocitrate were being absorbed. 
First pass metabolism to citric acid was observed but this metabolism was not 
commensurate with the poor rate of absorption. Studies utilising tricarballylate, 
a known inhibitor of tricarboxylic acid transport in the intestine, indicated that 
the disappearance of phosphocitrate from the intestinal lumen was not affected 
by the presence of this transport inhibitor. Consideration of this and everted 
sac data gave credence to the suggestion that phosphocitrate transport did not 
involve an established tricarboxylic acid transporter. 
A preliminary investigation was made into the possibility of improving 
the oral bioavailability of phosphocitrate with aliphatic ester prodrugs of 
phosphocitrate. Initially the approach was to investigate the synthesis and 
ultimate benefit of short (ethyl) and medium chain (octyl) esters. The triethyl 
ester of phosphocitrate was synthesised and trialled but the isolation and 
purification of the trioctyl ester was not possible within the time frame of these 
studies. 
Conclusions reached in this study were that phosphocitrate was 
absorbed following oral administration but that the extent of absorption was 
limited. Triethyl phosphocitrate was prepared in an attempt to improve the 
transport characteristics of phosphocitrate. Plaque calcification was not 
reduced following the administration of this ester. The prodnig approach was 
discussed as a possible avenue for improving the absorption of phosphocitrate. 
ACKNOWLEDGEMENTS 
I wish to sincerely thank my supervisor Dr. J.D. Sallis for his support, 
guidance and patience throughout the course of these studies. I especially want 
to express my appreciation for his valuable guidance, encouragement and 
critical assessment during the preparation of this manuscript. 
I would also like to thank Prof. M. G. Clark for his continual support of 
my enrolment and use of departmental facilities. 
Special thanks to all members of the biochemistry department. 
Especially to my fellow students Ravi Shankar, Harold Kamperman and John 
Meehan. Especially to John Meehan for his encouragement and help in the 
manuscript preparation and to Harold Kamperman for valuable discussion and 
assistance. The assistance of Dr. D.R. Woodward with his knowledge of 
statistics, foreign langauge translations and access to computor facilities is 
much appreciated. 
Valuable technical assistance has been provided by numerous people 
including Mr. J.E. Jordan, Mrs. R. Thomson and Ms. B. Rees. However, very 
special thanks must go to Maree Anderson for her expert assistance in many 
areas. I would like to acknowledge and thank the staff and services of the 
animal house. 
Thanks also to Diagnostic services for their use of facilities and the 
shelter of employment. 
In matters not entirely unrelated to the study and preparation of this 
thesis I would like to thank my Yoga teachers Swamis Alokananda and 
Ajnananda for valued support and insights into life. 
CHAPTER 1 
INTRODUCTION 
1.1 	CALCIFICATION - CALCIFIC DISEASES 
Calcification is a widespread biological phenomena occurring either as a 
physiological or a pathological process. It is the most ubiquitous of all the 
biomineralisation processes where two thirds of all biominerals contain calcium 
(L,owenstam, 1981). Calcium phosphates, specifically hydroxyapatite, are the 
most common types of calcium salts in higher vertebrates but additionally, 
carbonate, oxalate and pyrophosphate salts also occur (Russell et al., 1986). 
The regulation of normal calcification is a complex procedure involving 
the controlling activity of a range of effectors. These include collagen, 
pyrophosphate, proteoglycans, osteocalcin and osteonectin (Williams and 
Frolik, 1991) which are in turn inhibited or stimulated by a further range of 
hormones and growth factors. Two general theories are proposed for the 
mechanism of initiation of calcification (Williams and Frolik, 1991). One of 
these, the nucleation theory, states that for calcification to occur a highly 
ordered nucleation site must exist. This site, which is believed to be created by 
collagen fibrils, ensures an ordered interaction of crystal substrates in a spatial 
conformation which allows crystallisation to occur. The second theory focuses 
on the involvement of matrix vesicles in the initiation process whereby these 
vesicles have various functions including, concentrating calcium and phosphate 
at the nucleation site and providing enzymes for the removal of inhibitors to 
crystal growth. However it is possible that both theories have a role, such that 
in mature bone, calcification is initiated by nucleation whereas in cartilage and 
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early embryonic bone, where there is no obvious relationship between collagen 
and initial crystallisation, the process is controlled by matrix vesicles. 
The functional necessity of normal calcification in bone and teeth 
formation is obvious but unfortunately abnormalities, including osteoporosis 
(Nordin et al., 1984) and Paget's disease (Russell, 1984), arise when lack of 
control occurs. Additionally, a vast range of pathologies have been described 
which involve the abnormal calcification of tissues other than bone (Table 1.1) 
and these are usually referred to as ectopic calcification (Anderson, 1983). 
Sometimes a characteristic bone matrix forms (termed heterotopic 
calcification), and includes diseases such as myositis ossificans progressiva, post-
surgical or trauma complications and ankylosing spondylitis (Russell and Kanis, 
1984). 
Calcification which does not involve the formation of an identifiable 
bone matrix is traditionally subdivided into two groups, namely dystrophic and 
metastatic calcification. Intrinsic in the mechanism of metastatic calcification is 
the elevation of circulating levels of calcium and phosphate. Resultant 
alterations in the physicochemical and physiological equilibria can result in the 
formation of amorphous calcium phosphate leading to crystal formation. 
Metastatic calcification is common in the kidney, stomach and vascular system 
and has been associated with hyperparathyroidism, neoplasms, milk-alkali 
syndrome, hypervitaminosis D and tumoral calcinosis (Black and Kanat, 1985). 
Dystrophic calcification however does not involve elevated serum 
calcium and phosphate levels but is a response to tissue injury. The mechanism 
of initiation of this form of calcification is poorly understood but the 
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Table 1.1 Summary of Calcification Types 
Normal Calcification 
Bone, teeth and cartilage 
Pathological Calcification 
Heterotopic 
Involves a characteristic bone matrix 
- myositis ossificans progressiva 
- post surgical and trauma complications 
- paraspinal calcification (e.g. ankylosing spondylitis) 
Metastatic 
Calcification results from hypercalcaemia or hyperphosphataemia 
- tumoral calcinosis 
- hypervitaminosis D 
- neoplasms 
- milk alkali syndrome 
- hyper parathyroidism 
- chronic renal failure 
Dystrophic 
A response to tissue injury (e.g. necrosis, trauma) 
- monckebergs medial calcinosis 
- scleroderma 
- tympanosclerosis 
Oystal deposition disorders 
- hydroxyapatite 
- octacalcium phosphate 
- tricalciumphosphate 
- calcium pyrophosphate 
Urolithiasis 
Calcium oxalate and/or calcium phosphate stones 
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(based on Russell and Kanis, 1984) 
involvement of mitochondria and/or matrix vesicles in the accumulation of 
calcium following damage to homeostatic mechanisms is almost certainly 
involved (Anderson, 1983). Diseases in which dystrophic calcification is 
observed include scleroderma, dermatomyositis and Monckebergs medial 
calcinosis. Further, the process can be a natural part of ageing especially as 
regards calcification of the pineal gland and blood vessels. 
Several widespread, major disease states involve calcification as part of 
their progression. Atherosclerosis (McGill, 1988) is a major calcific disease 
involving dystrophic calcification. The term atherosclerosis actually refers to a 
number of disease states but all primarily involve anatomical and functional 
degeneration of some part of the vascular system. Fleckenstein et al. (1990) 
regard calcium overload of the arterial walls as a primary pathogenic factor 
leading to arterial destruction. Additionally, atherogenesis involves calcium 
mediated stages including changes in membrane permeability, cell proliferation, 
cell migration and the secretion of extracellular matrix proteins (Kjeldsen and 
Stender, 1989). 
Other common disease states which are broadly associated with 
calcification are those involving crystal deposition in joints. These diseases are 
varied and involve the appearance in and around joints of calcium salts. Basic 
calcium phosphate (BCP) deposition encompasses the appearance of 
octacalcium phosphate, hydroxyapatite or tricalcium phosphate (whitlockite) in 
joints (Halverson and McCarty, 1989). In addition calcium pyrophosphate 
dihydrate (CPPD) (Ryan and McCarty, 1989) and calcium oxalate (Reginato, 
1989) deposition have also been described. The appearance of crystals in joints 
can lead to the destruction of surrounding membranes and may result in severe 
ongoing trauma and inflammation (Terkeltaub et al., 1989). 
4 
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Urolithiasis is a broad term which refers to the precipitation of insoluble 
components of urine leading to the deposition of crystals (calculi) within the 
urinary tract (Robertson, 1984). It is estimated that between 50 and 80% of 
stones contain calcium, mainly present as calcium oxalate and sometimes as 
calcium phosphate. Of the remainder, urate, magnesium ammonium phosphate 
and cysteine stones are frequently observed. However it is thought that small 
crystals composed of calcium phosphate can provide a nidus for the growth of 
most stones. 
Modern surgical techniques have created their own problems with regard 
to calcification. Encrustation of implants and catheters with calcific deposits 
can affect their longevity. Calcium phosphates have been detected in mineral 
deposits attached to urinary catheters (Cox and Hukins, 1989) and Levy et al. 
(1985) has described similar encrustations associated with bioprosthetic heart 
valve implants. Dysfunction in the later case can result from stenosis or 
secondary calcific tearing of the leaflets (Johnston et al., 1990). 
1.2 	INHIBITION OF CALCIFICATION 
Given the myriad types of calcific diseases, it is clear that effective 
inhibitors might be seen as crucial in preventing the initiation or progression of 
these disease processes. The metastable nature of calcium and phosphate ions 
in extracellular fluids has long suggested the possibility that naturally occurring 
inhibitors of calcium salt formation might exist. Sindhu et al. (1989) listed 
magnesium, zinc, fluoride, stannous ion, citrate, pyrophosphate, ribonucleic 
acid, and acidic glycoproteins as naturally occurring inhibitors of urolithiasis. In 
fact urine itself has a noticeable inhibitory effect on hydroxyapatite crystal 
formation (Hansen et al., 1976) and Ogawa et al. (1986) found that salts of 
pyruvic acid and bicarbonate inhibited experimental oxalate urolithiasis. 
Meyer and Fleisch (1984), whilst suggesting that quantitatively most of 
the inhibitory power responsible for metastability in blood was probably due to 
high molecular weight substances, recognized that magnesium, pyrophosphate 
and citrate ions are important low molecular weight inhibitors of calcification in 
blood. Naturally occurring pyrophosphate and longer chain synthetic 
polyphosphates are powerful inhibitors of calcification in vitro (Francis, 1969). 
However these compounds were found to be highly unstable in vivo (Russell 
and Smith, 1973). Jung et al., (1970) found that pyrophosphate disappears 
rapidly from the bloodstream. Additionally, the compound is not effective when 
administered orally (Fleisch and Russell, 1977). These overall characteristics 
leave pyrophosphate unsuitable for clinical use. 
The search for more stable analogs of pyrophosphate led to the 
examination of a group of compounds now known as the bisphosphonates 
(diphosphonates). The P-O-P bonding arrangement of pyrophosphate is 
replaced by a P-C-P arrangement in the diphosphonates adding stability but 
unfortunately rendering the molecules enzymatically non-metabolisable. These 
compounds have been trialled extensively and shown to be very effective 
inhibitors of ectopic calcification (reviewed by Russell and Smith, 1973; Fleisch 
and Russell, 1977; Fleisch, 1981; Fleisch, 1983) and unlike pyrophosphate the 
diphosphonates - can be absorbed from the intestine (Michael et al., 1972), 
although the amounts transported are usually very low. 
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Etidronate (EHDP), the most commonly reported diphosphonate has 
been shown to inhibit vitamin D3 induced aortic calcification in rats (Francis et 
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al., 1969). 	However complications in the long-term administration of 
diphosphonates have limited their use. The diphosphonates have cellular 
effects and possible toxic implications in terms of bone growth (Miller et al., 
1985). Dichloromethylidene biphosphonate (C12MDP), another compound in 
the series, which has been used to treat malignancy induced hypercalcaemia has 
nephroto)dc potential (Alden, 1990). Overall, the toxicity and poor oral 
absorption of diphosphonates has resulted in these compounds having limited 
clinical use. However C12MDP and 4-amino-1-hydroxybutylidene-1,1- 
diphosphonate, unlike EHDP, have the advantage of not inhibiting skeletal 
mineralisation at doses that are required for inhibition of bone resorption and 
are used in the treatment of Paget's disease (Adami et al., 1986) 
A totally different class of compounds which may exert strong influence 
on calcific processes are the calcium antagonists (Godfraind, 1987). These 
agents modulate the entry of calcium into cells through selective or nonselective 
mechanisms. The compounds have strong anti-hypertensive action and effects 
on the vascular system, heart, cardiovascular hormones and renal function have 
been observed (Stniyker-Boudier. et al., 1990). They have been trialled as 
antiatherogenic agents in animal models and might conceivably prevent the 
toxic effects of excessive calcium accumulation by cells. The inhibition of 
arterial smooth muscle cell proliferation may also play a role (Struyker-Boudier 
et al., 1990). However definitive conclusions concerning their usefulness as 
inhibitors of atherogenesis have not been made (Kjeldsen and Stender, 1989). 
Concerning anticalcifying compounds generally, it is recognised that for a 
compound to have anticalcifying ability certain structural requirements exist 
(Williams and Sallis, 1982), as for many the mode of action of these compounds 
is thought to be via binding to charged sites on the growing crystal surface. 
Termine and Conn (1976) suggested that the presence of two phosphate 
moieties within the inhibitor molecule was important. More recently Williams 
and Sallis (1982) conducted detailed studies which indicated that strong 
inhibition could be obtained with compounds which contained one phosphate 
and multiple carboxylic acid groups in close proximity. 
1.3 	PHOSPHOCITRATE - A PERSPECTIVE 
Phosphocitrate (PC) (Figure 1.1) is one of the most potent naturally 
occurring anticalcifying agents so far recognised. The molecule has a highly 
polar nature and it is the spatial arrangement of the ionisable groups, whereby 
three carboxyl groups and a phosphate moiety radiate from a tetrahedral carbon 
atom, which appears to confer the powerful inhibitory potential (Williams and 
Sallis, 1979; Williams and Sallis, 1982). PC is naturally occurring being found in 
low concentrations in rabbit liver and kidney mitochondria (Williams and Sallis, 
1981) and possibly the hepatopancreas of the blue crab (Callinectes sapidus) 
(Lehninger, 1983). In addition, synthetic PC is available as a result of synthetic 
strategies devised in three different laboratories (Meyer et al., 1959; Williams 
and Sallis, 1980; Tew et al., 1980). 
Whilst it was first hinted by Meyer et al. (1959) that PC might have 
biological significance, the first real notions concerning the implications of PC 
as an anticalcifying agent came in a publication by Howard (1976). However 
until sufficient synthetic material became available in the early 1980's PC could • 
not be tested. Using non-biological physical-chemical assays, PC has been 
found to be a powerful inhibitor of amorphous calcium phosphate conversion to 
hydroxyapatite (Williams and Sallis, 1979; Reddi et al., 1980; Tew et al., 1980; 
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Figure 1.1 The structure of PC 
(Williams and Sallis, 1981). Further, early in vivo studies investigating the role 
of PC as an inhibitor of mitochondrial calcification (Tew et al., 1981a; 
Lehninger, 1983) and nephrocalcinosis (Tew et al., 1981b; Gimenez et al., 1982) 
confirmed that PC was a powerful anticalcifying agent in vivo. 
Since then PC has been studied using various experimental animal 
models that describe calcific disease processes. Concerning urolithiasis, the 
inhibition of nephrocalcinosis by PC might imply that the inhibitor has potential 
to be active in the inhibition of calcium phosphate urinary stone formation. 
Certainly, it has been demonstrated that PC can reduce mixed magnesium 
(struvite and newberyite) stone formation (Sallis et al., 1988). This data was 
interesting because it showed that PC can influence mineral formation outside 
of calcium containing structures. However, regarding calcium oxalate, the main 
type of calcium containing urinary stone, PC did not appear to have a strong 
influence in vivo (Brown and Sallis, 1985; Sallis et al., 1989). 
One area of potential usage for PC is in the field of crystal deposition 
disorders. The alleviation of hydroxyapatite and calcium pyrophosphate crystal 
induced polymorphonuclear leukocyte membranolysis by PC (Sallis et al., 1989) 
alludes to the possibility that this compound may have an important role in 
ameliorating the damaging effects of osteoarthritis and chondrocalcinosis. 
More recently, Cheung et al. (1990) have demonstrated inhibition of basic 
calcium phosphate crystal induced mitogenesis by PC. Specifically PC inhibits 
crystal induced expression of c-fos in a way that is suggestive of PC acting at a 
cellular level. 
Another field that has been explored with respect to the actions of PC is 
atherosclerosis (Shankar, 1986). Accumulation of calcium, by myocardial fibres, 
1 0 
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vascular smooth muscle cells and elastic elements in the arterial walls, can be 
cytotoxic leading to the deposition of calcium salts (Fleckenstein et al., 1990). 
The inhibition of dystrophic calcification of arteries by PC was demonstrated 
using an aortic transplant model (Shankar et al., 1984b) and further to this PC 
has been reported to inhibit 45Ca2 + uptake by smooth muscle cells in primary 
culture (Shankar and Sallis, 1985). This latter finding is interesting because it 
appears that a direct cellular action could have occurred. Additionally it was 
observed that PC acted by a different mechanism to the calcium channel 
blocker diltiazem, because when the compounds were applied together their 
effects were additive. Consequently a possibly unique therapeutic role for PC in 
atherogenesis was proposed. 
In experiments with a hyperlipidaemic rat model PC was found to reduce 
monocyte adhesion to arterial endothelium. This latter finding also has 
important implications that PC may be acting at a cellular level. Further to this 
PC inhibits low density lipoprotein (LDL) (Ward et al., 1987) uptake and 
degradation by aortic smooth muscle cells. This process is thought to at least 
partly involve competition between PC and LDL receptors for binding to 
positive domains on the lipoprotein. However a direct cellular effect may be 
possible because heparin on a molar basis was less effective than PC. 
Interestingly, phosphoisocitrate which has the same charge as PC but a different 
chemical structure was less active in preventing LDL uptake. It is possible that 
-  PC, based on its high negative charge to size ratio and specific stereochemistry 
may have a range of possible in vivo effects that involve binding to regions of 
positive charge. 
Following the indications that PC had anti-atherogenic potential, Tsao et 
al. (1988) investigated the compound with respect to its effect on the 
calcification of bovine pericardium used in bioprosthetic heart valves. Using a 
rat model, dystrophic mineralisation of these valves was found to be decreased 
following local delivery of PC with subcutaneously implanted osmotic 
minipumps. The authors were unable to detect any adverse effects and 
concluded that PC may have future clinical importance in this area. 
PC trials have so far been restricted to experimental animal models 
leaving therapeutic and any potential toxicity in humans to be determined. 
One of the problems with using anticalcifying agents at therapeutic dose levels 
is the potential for toxic effects on normal bone mineralisation. To date no 
evidence of toxicity has been found, as might be expected given that PC is found 
in soft tissue mitochondria and that the likely breakdown products of PC, citrate 
and phosphate, are also naturally occurring. Additionally, an enzymatic 
biological synthesis of PC has recently been reported (Moro et al., 1990). More 
importantly Reddi et al. (1980) found an absence of effect on bone and cartilage 
mineralisation, and Tew et al. (1981b) found that PC did not have any 
detrimental effects on bone growth. Shankar (1986) conducted studies (up to 90 
days) investigating metabolic parameters and bone histology, finding no side 
effects. Actually the compound was observed to normalise some adverse effects 
of an arteriosclerotic diet by normalising serum creatinine and uric acid levels. 
1.4 	ORAL ABSORPTION 
The potential of PC to be used as a drug has not been fully delineated to 
date and one of the major questions to be answered concerns administration. 
Being mindful that clinically oral delivery is preferred, the most efficient way to 
administer PC needs to be determined. Drug efficacy itself depends on 
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absorption, distribution, biotransformation and elimination. These are dynamic 
processes which contribute to the bioavailability of a drug species and ultimately 
determine the usefulness of a drug. Many factors including psychological 
barriers preclude the use of some routes of administration for drugs leaving oral 
dosing as the preferred option. In this respect the question of PC oral 
availability is crucial and needs to be examined before the development of 
appropriate dosage forms. 
Gastrointestinal absorption is complex, being influenced by a variety of 
physiological and physicochemical parameters. Kararli (1989) includes 
gastrointestinal motility, gastric emptying, intestinal blood and lymph flow, bile 
salts, surface pH of the mucosa, the unstirred water layer and colonic microflora 
as relevant factors. Absorptive mechanisms exist at different sites within the 
alimentary canal. Absorption of drug molecules from the stomach has been 
observed experimentally, but is not generally regarded as significant if gastric 
emptying is unimpeded. Buccal and colonic absorption while notable for some 
compounds will not be considered in detail here because intestinal absorption is 
the most common route of entry into the body for drugs and needs to be 
explored first. The mucosal barrier (Houston and Wood, 1980) is quite 
complex. The lumen contents are separated from the mucosal cells by a 300 
micron unstirred water layer which maintains an acidic microenvironment 
extending 20 microns from the microvillus. The acidic microenvironment has 
important consequences with respect to ionization of charged groups. The 
microvillus and associated surface coat present the final barrier to transport. 
Having reached the mucosal surface of an epithelial cell, a drug 
molecule has five pathways at its disposal for transport across the membrane. 
Schwenk (1987) describes the mechanisms of paracellular diffusion, 
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transcellular diffusion, facilitated diffusion, active transport and endocytosis in 
relation to solute absorption. Most drugs, unless they have a direct similarity to 
biological species which are normally absorbed via active transport mechanisms, 
are absorbed by the passive transcellular route (Houston and Wood, 1980). In 
addition, Schwenk (1987) regards the paracellular route as important for many 
compounds. Here the motive force for absorption is the solvent drag that 
accompanies the paracellular absorption of water. 
Regarding the intestinal transport characteristics of PC there appears to 
be little information available in the literature which might help answer the 
question of PC absorption. The absorption of citrate and other tricarboxylic acid 
cycle intermediates from the gastro-intestinal tract has been poorly researched. 
Browne et al. (1978) studied citrate absorption from the small intestine of the 
hamster using everted sacs, and presented evidence that a specific mechanism is 
involved with absorption. A saturable Na-dependant mechanism was observed 
and furthermore, this transport was against a concentration gradient. Because 
tricarboxylic acid intermediates are extensively metabolised during transport 
(Browne et al., 1978), Wolffram et al. (1990) used brush border membrane 
vesicles for their transport studies. The latter study reported a pH effect 
whereby the protonated species (citrate2- and citrate l-) were better transported 
than the trivalent species. 
The possibility of PC transport being by the same mechanism as 
described for intestinal citrate uptake is not known. Certainly it would be 
• anticipated that physicochemical parameters might determine the rate of PC 
absorption across the mucosal barrier. Factors, which include molecular size, 
lipophilicity and ionisation, that might influence absorption are discussed in 
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several general reviews and books (Houston and Wood, 1980; Peng, 1983; 
Kararli, 1989; Ansel and Popovich, 1990). 
For PC the ionisability of the phosphate and carboxylate groups is 
especially relevant with respect to transcellular diffusion. For most water 
soluble drugs, absorption potential can be described according to the 
Henderson Hasselbach equation (pH = pK a + log Ci/Cu for acids, where Ci = 
ionised concentration and Cu = unionised concentration). Effectively this 
states that as the pH is lowered, for any given pK a, the ratio of unionised to 
ionised compound is increased. A large body of evidence supports the concept 
that most drugs are absorbed in the unionised form (Schanker, 1971). Hence 
from a consideration of the pKas for PC (Ward, 1986), which are pKa 1 = <2, 
pKa2 = 3.67, pKa3 = 5.15, pKa4 = 7.69, pKa5 = 13.56; it is immediately 
apparent that PC will always be highly charged at the physiological pH of the 
intestinal lumen. 
The ionisation constant data for PC allows for an interesting comparison 
with a well documented literature example. EHDP is not well absorbed and a 
consideration of the pKa data (pKas are 1.7, 3.1, 7.5 and 11.5) (Gural et al., 
1985) suggest it is highly ionised at physiological pH. Michael et al. (1972) found 
absorption to be less than 10% in the rat, rabbit and monkey whilst ranging 
from 13.6 to 21.1% in the dog depending on age. Other investigators 
(Wasserman et al., 1973; Gural et al., 1985) have reported similar findings in 
animal studies with EHDP. Although Gural et al. (1985) found a dose 
dependant relationship, it appears high absorption rates at high dose levels 
correlated to structural alterations in the mucosal membrane. Recker and 
Saville (1973) using human subjects and a variety of techniques estimated 
absorption values ranging between 1.49% and 7.19%. 
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1.5 	PRESYSTEMIC METABOLISM - THE EFFECT 
ON ABSORPTION 
Presystemic metabolism is an aspect of gastrointestinal absorption that 
needs to be considered and a range of enzymes which are active in 
biotransformation have been described. For convenience, enzymatic 
metabolism of xenobiotics has been divided into two groups. Phase 1 reactions 
include examples such as oxidation, hydrolysis, reduction, dealkylation, and 
desulphuration while phase 2 reactions involve conjugation to an endogenous 
metabolite (eg. glycine, glucuronic acid) (Hartiala, 1973; Caldwell and Varwell 
Marsh, 1982). 
Regarding PC, enzymatic hydrolysis to citrate is possible, in vitro. 
Accordingly, alkaline phosphatase has been used in the laboratory for analytical 
purposes but the assay conditions require a pH of 10.5 with a large excess of 
enzyme. Similarly, acid phosphatase, at pH 4.8, has been used for hydrolytic 
purposes in the detection of PC on TLC plates (Williams and Sallis, 1980) but 
again relatively large amounts of enzyme are required for phospho-hydrolysis to 
occur. Enzymatic metabolism, in vivo, has not been documented so possible in 
vivo hydrolysis within the gastro-intestinal tract would need to be explored. 
Clearly enzyme activity in the intestine (Renwick and George, 1989), liver 
(George and Shand, 1982) and lung (Routledge and George, 1982) can have a 
major effect on bioavailability through biotransformation of a drug species prior 
to entry into the systemic circulation. 
To be absorbed from the intestine, a drug species needs to be resistant to 
chemical and enzymatic transformation in the stomach and lumen before, as 
indicated above, facing a complex range of biotransforming enzymes in the 
intestinal epithelia. This metabolic barrier acts essentially to protect the 
organism against potentially toxic substances but it is sometimes a distinct 
barrier to convenient drug therapy. Compounds which are metabolised by 
intestinal tissue include pyridoxal 5'-phosphate (Middleton, 1986), 
chlorpromazine (Curry et al., 1971), Leu-Enkephalin (Freidman and Amidon, 
1991), organic nitrate esters (Posados et al., 1988) and thiamin phosphates 
(Gastaldi et al., 1988). Detailed compilations of gut metabolism are given by 
Routledge and Shand (1979); Caldwell and Varwell Marsh (1982). 
Another aspect of drug metabolising activity is that this activity is not 
uniform within the intestine. This fluctuation can be local or more general, 
implying the existence of gradients lengthwise within the gastrointestinal tract 
(Renwick and George, 1989). Weiser et al. (1986) describe a number of 
epithelial enzymes which change in activity along the length of the intestine. 
Alkaline phosphatase for example has high duodenal activity but displays a 
sharply decreasing gradient towards the distal portions of the intestine. The 
impact of the intestinal micro flora on metabolism and absorption is also 
relevant (Goldman, 1982). 
1.7 	RESEARCH AIMS 
The overall purpose of these studies was to investigate the effectiveness 
• of PC when delivered by the oral route. As all studies to date have used the 
intraperitoneal route for testing efficacy, a comparison of the effectiveness of 
PC on calcification when delivered by the two administration routes was 
thought necessary. The need to determine the actual extent of uptake from the 
intestine using specialised in vitro and in vivo techniques was also envisaged. 
17 
Insights into the absorptive process thus obtained, would be expected to provide 
information on how to maximise the delivery of PC to the systemic circulation. 
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CHAPTER 2 
INVESTIGATION OF PHOSPHOCITRATE ORAL BIOAVAILABILITY 
USING A CA.LCERGY MODEL 
2.1 	INTRODUCTION 
Previous studies on the effectiveness of PC in preventing biological 
calcification have utilised the intraperitoneal route of administration. The dose 
necessary for an effective biological response has varied depending on the site 
of calcification. This indicates that biological parameters may influence the 
biodistribution of PC, which is not unexpected given the unusual physico-
chemical nature of PC. Information concerning the bioavailability of PC 
following oral administration is a necessary part of any pharmaceutical 
evaluation of this compound as absorption from the gastrointestinal tract has 
long been the preferred route of administration for most therapeutic agents 
(Ranade, 1991). 
In the present chapter calcergy (Doyle et al., 1979) is used as a model to 
compare the systemic bioavailability of PC when given orally versus an 
intraperitoneal injection. The method initially developed by Seyle et al. (1962) 
involves the subcutaneous injection of a dilute metal salt or oxidising agent 
which will induce the formation of a calcergic plaque. Seyle and Berczi (1970) 
list 25 compounds that can elicit this response in the rat. Accordingly a local 
calcergic reaction can be induced in the mature collagenous connective tissue of 
the dorsal fascia and several specific events associated with this process have 
been noted (Hirsch et al., 1984). Transient hyperaemia and increased vascular 
permeability result within several hours. This vascular reaction has been linked 
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to the degranulation of mast cells which has been noted 5 min after injection 
(Bridges and McClure, 1972). The calcergic reaction is well established within 
24 h, along with an accumulation of macrophages and multinucleated giant cells 
at the edges of the expanding calcific zone (Hirsch et al., 1984). Ultrastructural 
studies (Boivin et al., 1987) indicate that demineralisation begins within 15 days. 
The structured nature of calcergy development indicates that it should be 
suitable as a model for the screening of anticalcifying agents. McClure (1979) 
compared the inhibitory effects of pyrophosphate and EHDP on simple calcergy 
and Doyle et al. (1979) used potassium permanganate (KMn04) induced 
calcergy as a means of studying the effects of various drugs on hydroxyapatite 
crystal deposition. The latter authors used X-ray spectroscopy to demonstrate 
that the plaques were comprised of hydroxyapatite and Boivin et al. (1987) 
observed needle-like structures, apatite in nature, deposited between and 
around collagen fibrils. In the present studies ICMn04 was used to induce 
calcergy and reduction in calcification from treatment with PC was evaluated as 
a response to the presence of PC in the systemic circulation. 
2.2 	METHODS 
2.2.1 	General reagents and equipment 
Reagents used were AR grade when possible. Buffers and solutions were 
made with double distilled water. Equipment used included an atomic 
absorption spectrophotometer (Varian techtron, model 1000) and Beckman 
(DU-30) spectrophotometer. 
2.2.2 	Synthesis of phosphocitrate 
PC was prepared by a combination of methods described by Tew et al. 
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(1980) and Williams and Sallis (1980). The tertiary hydroxyl group of triethyl 
citrate was phosphorylated using o-phenylene phosphochloridate, the latter 
reagent being synthesised by the method of Khwaja et al. (1970). 
Phosphorylation was followed by hydrogenation and base hydrolysis in the 
presence of CaC12. Final purification involved cation exchange on AG.50W-X8 
followed by gradient elution with bicarbonate buffer using the anion exchanger 
AG.1-X8. PC which was characterised by previously published methods 
(Williams and Sallis, 1980; Williams and Sallis, 1981) had a molecular weight of 
450. 
2.2.3 	Induction of local calcergy 
Male Hooded Wistar rats weighing 200 g were injected subcutaneously 
with 200 Al of a freshly prepared KMn04 solution (1 mg/m1). The rats were 
injected in two positions either side of the spine in the interscapular region. The 
calcific plaques were allowed to develop for a period of 10 days after which the 
rats were killed by anaesthetic overdose. The plaques were excised for later 
analysis. In all respects the animals remained healthy following the treatment 
and attained the same body weight at the end of the 10 day period. 
2.2.4 	Analysis of calcific plaques 
2.2.4.1 	Treatment of plaques 
Immediately after excision the plaques were blotted dry on tissue paper, 
plunged into liquid nitrogen and then immediately weighed. Storage was at 
-20°C. Plaques were ground into a powder using an aluminium mortar and 
pestle which was kept cold in a bath of liquid nitrogen. Aliquots of powder (15- 
25 mg) were quickly weighed and placed in glass vials. A solubilisation mixture 
comprising of 70% perchloric acid (200 Al) and 30% hydrogen peroxide (400 
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Al) was added before fitting the vials with acid resistant teflon caps and 
digestion at 80°C for 2 h. After cooling, the contents of each flask was made up 
to 5 ml with water. 
	
2.2.4.2 	Estimation of calcium 
The calcium content of plaques was determined using atomic absorption 
spectrophotometry. For measurement, aliquots of plaque digests (0.5 ml) were 
diluted to 10 ml with a lanthanum chloride solution (50,000 ppm La 3 ). 
Standards were in the range 0-2.5 Amol Ca 2+ / m1). 
2.2.4.3 	Estimation of phosphate 
The phosphate content of plaques was determined using the method of 
Fiske and SubbaRow (1925). Any interference with the assay due to the 
presence of the tissue oxidising mixture was prevented by the addition of 
sodium sulfite (100 pi, 33% Na2S03.7H20). Standards in the range 0-1.0 pmol 
PO4 were used. 
2.2.4.4 	Histological evaluation of plaques - von Kossa stain 
Plaques were fixed in 10% phosphate buffered formol-saline at pH 7.4 
for 24 h. The tissue was then dehydrated using ascending grades of ethyl alcohol 
(50-100%) and cleared in xylene before being infiltrated and embedded with 
paraffin wax. Sections (5 pm) were cut using a microtome and applied to slides 
which were deparaffinised in xylene. The slides were treated with 5% silver 
nitrate and exposed to a bright light (60 W) for 60 min. After rinsing in water, 
immersion in 3% sodium thiosulphate and again rinsing in water, the slides 
were counterstained with van Geison stain. Finally sections were dehydrated, 
cleared and mounted. 
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2.2.5 	Administration of PC 
Trials involving inhibition of calcification by various routes of 
administration were made. Compounds were administered by gavage (oral), 
intraperitoneal or subcutaneous injection. Rats were divided into groups (6-8 
rats/ group) and administered the test substance twice daily (9.00 am and 5.00 
pm). Rats designated as a control group received an equivalent volume of 
isotonic saline alone and it has been demonstrated previously that citrate and 
phosphate do not have an effect on in vivo calcification when compared to PC 
(Ward et al., 1986). On day one of each trial, rats were dosed with PC 1 h before 
administration of KMn04. 
2.2.6 	Evaluation of data 
Plaque differences were examined in several ways. In each experimental 
group, plaques were weighed and analysed for calcium and phosphorus. Data 
was compared using the single tailed student t-test. Calcium/phosphorus ratios 
were compared for some experimental groups. 
2.3 	RESULTS 
A subcutaneous injection of KMn04 induced the formation of a 
calcergic plaque (Figure 2.1). The plaques were demonstrated to contain 
calcium and phosphate by analysis of these parameters and by staining using 
the von Kossa method (Figure 2.2). Typically the plaques were round to oval in 
shape and of a milky white appearance. During early studies, plaque dimensions 
were measured. The average dimensions for plaques examined for this 
parameter were 16 mm by 10 mm (n = 16). Plaque thickness ranged between 1-3 
MM. 








































































































Differences in plaque formation as a result of inhibitor administration 
have been expressed as changes in mean total weight. Analyses of plaque 
calcium and phosphorus were also performed. Changes in the total calcium and 
phosphorus content of plaques was found to mirror the changes in plaque 
weight. The concentration of calcium and phosphorus (per mg plaque) was 
calculated and found to be similar in all plaques regardless of plaque weight 
(Figure 2.3). Calcium/phosphorus ratios were consistent with the precipitated 
calcium salt being hydroxyapatite. 
The response of plaque weight to the intraperitoneal injection of PC was 
determined at six dose levels. Plotting mean response versus dose of PC yielded 
a curve (Figure 2.4). When rats were untreated, the mean value for plaque 
weight was 198 mg. Compared to the control group all doses except the lowest 
were highly significant (p <0.0005). The lowest dose (2.5 mg/kg/day) was 
marginally outside the significance level of 0.025 <p  <0.05. At 10 mg/kg/day, 
PC reduced plaque weight by 35%, increasing to 72% at 50 mg/kg/day and 88% 
at 100 mg/kg/day. 
Figure 2.5 shows the effect of intraperitoneal PC on the total calcium 
and phosphorus content of plaques at three doses. When PC was given at 50 
mg/kg/day the total calcium and phosphorus content of plaques was reduced by 
75% (p <0.0005) and 76% (p <0.0005) respectively. The reduction in plaque 
calcium and phosphorus increased to 90% and 91% respectively at the highest 
dose of 100 mg/kg/day. The lowest dose (2.5 mg/kg/day) did not produce 
statistically significant changes in plaque calcium and phosphorus (0.3 <p < 0.4). 
The response of plaque weight to oral dosed PC was measured when PC 
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Figure 2.3 The concentration of plaque calcium and phosphorus and 
calcium/phosphorus ratio in plaques as a function of plaque weight. As 
indicated in section 2.2.3 body weight was the same for all animals. Data 
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Figure 2.4 A dose response curve, plotted by linear regression (r =0.97), showing 
the effect of intraperitoneal administered PC on plaque weight. Control rats 
received an equivalent volume of 0.9% saline by intraperitoneal injection. Data 
represents mean + /- SEM. N values refer to the number of plaques and are 
shown in brackets for each dose; 0 (50), 2.5 (22), 10 (14), 15 (18),30 (16), 50 
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Figure 2.5 The effect of PC administered by intraperitoneal injection on the 
total calcium and phosphorus content of plaques. Data represents mean + /- 
SEM. N-values are in parentheses. 
Figure 2.6. The data for reductions in total plaque calcium and phosphorus 
levels at the two doses is presented in Figure 2.7. A statistically significant 
reduction in plaque weight of 13% (0.01<p <0.025) was obtained when PC was 
administered orally at 100 mg/kg/day. Reductions in plaque calcium of 10% 
(0.10<p <0.15), and plaque phosphate of 6% (0.20 <p <0.25) were not 
significant. The measured plaque parameters were reduced by 34% (p <0.0005), 
30% (0.0005 <p <0.005) and 24% (0.005 <p < 0.01) respectively at the 450 
mg/kg/day dose level. 
The equivalent intraperitoneal dose that corresponded to a 34% 
reduction in plaque weight, as observed for the oral 450 mg/kg/day dose, was 
approximately 10 mg/kg/day. This represented a difference of 45 times when 
the two routes of administration were compared. 
Administration of PC subcutaneously at the site of KMn04 injection 
resulted in complete prevention of plaque formation. However the development 
of haematomas at the injection site was apparent following daily subcutaneous 
administration of PC. 
2.4 	DISCUSSION 
The presence of hydroxyapatite in plaques formed after administration 
of dilute metal salts has been previously established (Doyle et al., 1979; Boivin 
et al., 1987). The present data confirms the validity of this model as analysis for 
calcium and phosphate in plaques indicated the presence of these elements in a 
ratio typical of hydroxyapatite. Trials with PC resulted in significant reductions 
in plaque weight following intraperitoneal administration but the response to 
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Figure 2.6 The effect of orally delivered PC on plaque weight. All rats were 
dosed by gavage and control rats received an equivalent volume of 0.9% saline. 
Data represents mean + /- SEM. N-values are in parentheses. 
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Figure 2.7 The change in total calcium and phosphorus content of plaques 
following oral administration of PC. Data represents mean + /- SEM. N-values 
are in parentheses. 
45 times the dose of PC had to be administered to reach an equivalent potency 
compared to an intraperitoneal dose. This highlights a problem in the passage 
of PC from the intestinal lumen to the systemic circulation. 
Previous studies, using a range of models, have demonstrated the overall 
effectiveness of PC in preventing unwanted calcification following 
intraperitoneal administration. Treatment with intraperitoneally injected PC in 
an infection stone forming model reduced stone weight by 73% (Sallis et al., 
1988). This compares with the 72% reduction in calcergic plaque weight 
obtained with an equivalent intraperitoneal dose of PC. Considerably lower 
doses (2.25 mg/kg/day) were needed to prevent dystrophic calcification of 
aortic segments transplanted to the peritoneal wall of rats (Shan.kar et al., 
1984b). This data supports the indications obtained here that the effectiveness 
of PC can be influenced by the route of administration. 
The distribution of PC into body compartments following non-targeted 
delivery probably means that only small amounts of PC actually reach the 
calcification site. This idea would seem to be verified as subcutaneous 
administration of PC (50 mg/kg/day) near the site of plaque formation 
completely inhibited the calcium salt deposition. Further studies investigating 
the dose response to subcutaneously administered PC might be useful in 
determining the real ability of this compound to prevent calcergy. This was not 
appropriate in this study as the model was primarily used to examine changes in 
bioavailability following oral administration. 
In these trials PC was delivered by gavage, leaving several factors as 
possible reasons for the reduced systemic effect of PC following oral delivery. 
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Figure 2.8 illustrates some potential limiting factors that might prevent the 
absorption of PC into the bloodstream. Chemical and enzymatic hydrolysis in 
the stomach and/or intestinal lumen might reduce the availability of PC at the 
mucosal surface. The highly charged nature of the PC molecule might prevent 
passage across the mucosal barrier. In relation to this, it is known that high 
charge can effect the membrane permeability of a compound and hence limit 
transport (Schanker, 1971). Other factors which can influence absorption 
(Renwick, 1982) include chelation to other compounds, intestinal mobility, gut 
transit time and exposure to intestinal microflora. 
First-pass metabolism in intestine and liver would reduce the amount of 
PC available within the systemic circulation. Enzymes which could theoretically 
hydrolyse PC are the alkaline (Fernley, 1971) and acid (Hollander, 1971) 
phosphatases. These enzymes have a ubiquitous tissue distribution and catalyse 
the hydrolysis of a wide variety of phosphate esters. Alkaline phosphatase is a 
membrane bound enzyme with high activity in gut tissue. However, although 
degradation of the PC molecule by phosphoryl esterase action has been 
considered by some authors (Reddi et al., 1980; Williams and Sallis, 1981) no 
definitive evidence has arisen from these investigations to support this notion. 
Interestingly, Shankar et al. (1984a) found that PC effectively inhibits calcium 
uptake by matrix vesicles, despite the presence of high alkaline phosphatase 
activity. Additionally, the active site in alkaline phosphatase which contains 
Zn2+ is sensitive to the charged nature of potential substrates (Fernley, 1971). 
Altogether these factors make it unlikely that this enzyme will have a marked 
effect on PC in vivo. 
Despite speculation concerning uptake and metabolism, PC has been 
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Figure 2.8 A simple schematic representation of possible barriers to PC 
absorption from the gastro-intestinal tract. 
orally. The limited systemic effect observed then indicates the need for more 
extensive investigations of the absorption process at the gut site. With more 
specific information, insights might be gained leading to appropriate 
formulations for improving the oral delivery of PC. 
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CHAPTER 3 
STUDIES ON PC ABSORPTION FROM THE GUT USING IN VITRO 
EVERTED SACS AND IN SITU INTESTINAL LOOPS 
3.1 	INTRODUCTION 
As indicated in chapter 2 the anticalcifying activity of PC and hence it's 
bioavailability appeared reduced following oral administration as compared to 
the intraperitoneal route. Whilst this information was intrinsically valuable, the 
need for data concerning the intestinal transport of PC was apparent. To help 
evaluate the likelihood of being able to successfully administer PC orally, 
experiments were conceived which might help gain an understanding of the 
absorption process concerning PC. 
Numerous models for studying gastrointestinal absorption have been 
reported in the literature (Houston and Wood, 1980; Csaky, 1984; Ings, 1984). 
In the early stages of investigating intestinal drug absorption the two most 
common strategies for experimentation are (1) in vitro methodology which 
involves the use of isolated gastrointestinal tissue and (2) in situ techniques 
which involve experiments on anaesthetised animals with an intact vascular 
network. 
According to Barr and Riegelman (1970) in vitro techniques can provide 
an indication of relative permeability and also information on the capacity of 
mucosal enzymes to metabolise drugs. A wide range of in vitro techniques exist 
and include everted sacs (Wilson and Wiseman, 1954), everted intestinal ring 
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slices (Stewart et al., 1986), isolated brush border membrane vesicles (Kessler et 
al., 1978), and isolated enterocytes (Kimmich, 1970; Pinkus, 1981). 
In order to gain insights into appropriate methodology for studying PC 
absorption, a study of the literature concerning citrate absorption was 
considered useful as although PC is structurally a unique compound, it 
nevertheless does have some structural homologies with citric acid. From early 
studies (Martensson, 1940) and more recently those of Behnke et al. (1966) it is 
clear that citrate can be recovered in the blood after perfusing citric acid in the 
intestine. Browne et al. (1977) reported using the everted intestinal sac model to 
study the gastrointestinal absorption of citric acid. Houston and Wood (1980) in 
a review on gastrointestinal absorption of drugs suggested that the everted sac 
model is particularly suitable for exploratory and screening work. The 
technique, with the creation of an artificial serosal chamber and exposure of the 
mucosal cells to a relatively large volume of oxygenated and mixed nutrient 
medium, allows permeability and any potential first pass effects to be 
investigated. 
In respect to in situ techniques, two methods, termed closed loops and 
perfused loops, are commonly used. Levine and Pelikan (1961) have described a 
relatively simple version of the closed loop which involves the surgical creation 
of a drug filled closed intestinal loop while the animal is lightly anaesthetised. 
The animal is then allowed to recover from the anaesthetic and the loop 
contents are measured at a designated time afterwards. Perfused loops involve 
the simulated passage of drug through the segment of gut being studied allowing 
samples to be obtained during the time course of the experiment. 
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Whilst elaborate in situ methodologies do exist (Hayton and Levy, 1972), 
Houston and Wood (1980) have described the closed loop method detailed by 
Levine and Pelikan as the most physiological of the in situ models. The 
procedure allows the animals to be ambulatory within 5 min of completing the 
cannulation procedure, hence minimising any effects of anaesthesia on the 
absorption process. The purpose of the studies reported in this chapter were to 
measure the in vivo uptake of PC from the lumen along with the in vitro passage 
of PC across the gut and any potential metabolism. 
3.2 	METHODS 
3.2.1 	General reagents and equipment 
Enzymes were obtained from Boehringer Mannheim (Australia). 
Equipment used included a Metabolyte shaking water bath (New Brunswick 
Scientific Co.) and a Ratio Fluorimeter (Beckman). 
3.2.2 	Analysis of PC and citrate 
Analysis of PC was according to the method described by Williams and 
Sallis (1980) using a coupled enzyme assay. Following preincubation of PC with 
alkaline phosphatase, malate dehydrogenase, NADH and citrate lyase were 
added and the conversion of NADH to NAD + was followed fluorometrically. 
The reaction sequence for this assay is PC-.citrate-q)xaloacetate- ■malate. 
3.2.3 	Everted sac preparation 
The method was similar to that described by Browne et al. (1978) based 
on an original description by Wilson and Wiseman (1954). Male Hooded Wistar 
rats weighing 200 g were killed by cervical dislocation. The small intestine was 
exposed by a midline incision and a 10 cm section beginning approximately 5 cm 
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posterior to the pyloric sphincter was surgically isolated and dissected away 
from the mesentery. 
The segment was washed free of particulate matter with isotonic saline 
at room temperature and then everted on a glass rod (0.D. 5.0 mm). The 
everted sac was closed at one end with a silk ligature, then filled with 1.0 ml of 
Krebs-Henseleit buffer containing 5 mM glucose (KHG; comprising 0.154 M 
NaCl (100 pts), 0.154 M KC1 (4pts), 0.11 M CaC12 (3pts), 0.154 M KH2PO4 
(lpt), 0.154 M MgSO4.7H20 (1pt), 1.3% NaHCO3 (21 pts), 0.130 mM glucose 
(5pts); Dawson, 1986). Once filled the segment was closed at the other end with 
a silk ligature. 
The sacs were incubated in 25 ml KHG in 50 ml Erlenmeyer flasks. 
Incubations were performed at 37 °C in a shaking water bath (80 oscillations / 
minute) under a gas phase of 5% CO2/ 95% 02. The buffer was prepared fresh 
each day from stock solutions, maintained at 37 °C and equilibrated with the 
same gas phase prior to being used for incubations. 
The fluid contained within the artificially created sac, and in contact with 
the serosal surface of the gut segment, was called serosal fluid and the fluid 
bathing the intestinal mucosa was termed the mucosal fluid. Test substances 
(PC and citrate) were added to the mucosal fluid in known concentrations 
according to the design of the experiment. Serosal fluid volume changes were 
determined by weight. 
3.2.4 	, 	In situ loop preparation 
Male Hooded Wistar rats weighing 200 g were lightly anaesthetised with 
ether and then maintained under halothane anaesthesia (fluothane, ICI 
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Australia) using a Boyles Apparatus (Fluotec MK. 2, Cyprane Ltd. UK.). The 
anaesthetic conditions were controlled at 1.5% halothane and 3000cc/min 
oxygen. The abdominal cavity was opened with a 1.5 cm midline incision. The 
appropriate region of intestine was externalised and a 10 cm section, starting 
approximately 5 cm posterior to the pyloric sphincter, was identified. 
A small incision was made 0.3 cm beyond each end of the 10 cm sections. 
A glass cannula was inserted into the distal end and held in place with a silk 
ligature. The segment was then rinsed free of its contents with isotonic saline at 
37°C. Air was gently forced from the loop before ligation of the proximal end. 
PC (22.5 /mop was introduced (via the cannula) as a solution in isotonic saline. 
The distal end was then carefully ligated as the cannula was withdrawn. The 
intestines which had been kept warm with a saline moistened pad (37°C) during 
surgery were returned to the abdominal cavity which was then sutured close 
before the rat was allowed to recover from the anaesthetic. The rats were aided 
in the maintenance of body temperature post-operatively through the use of a 
heat lamp. 
At timed intervals following the introduction of PC the rats were killed 
by cervical dislocation, the abdominal cavity opened and the segment quickly 
removed. The contents of the closed loops were retained and the loop twice 
washed with ice-cold distilled water.The washings were pooled with the original 
contents and the combined total volumes determined by weight. Solutions for 
assay were either stored frozen or maintained at 4 °C prior to an immediate 





Disappearance of PC from the intestinal lumen using an in situ technique 
was observed (Figure 3.1). The rate of disappearance of PC was initially rapid 
but slowed over the 60 min time course of the experiment. Examination of the 
data revealed that this was not a first order process. Additionally a steady but 
small linear increase in lumen citrate was noted. During the initial 10 min the 
lumen PC content was reduced from 22.2 pmol (22.2mM) to 11.3 pmol. This 
represents disappearance at the rate of 10.9 pmol/ 10 cm/ 10 min. At 60 min, 
lumen PC was reduced to 1.5 thmol which represents an overall rate of 
disappearance of 2.0 plri01/ 10 C111/ 10 min during the final 50 min. Lumen 
citrate was found to increase from 1.4 pmol at 5 min to 2.6 pmol at 60 min. 
Figure 3.2 shows the serosal transfer of PC after incubation of everted 
sacs with different concentrations of PC. In the presence of 1 mM PC, no PC 
was detected in the serosal fluid. Incubation with 5 mM PC resulted in transfer 
of 0.17 pmol/ 10 cm sac/ h. Transfer increased to 2.20 pmol/ 10cm sac/ h when 
incubations were in the presence of 15 mM PC. Additional to the serosal 
transfer of PC, it was noted that citrate transfer also occurred (data not shown) 
and it was apparent that the ratio of PC to citrate transferred increased as the 
initial incubation concentration of PC in the mucosal fluid increased. 
Another interesting aspect noted from the everted sac experiments was 
obtained from examination of the data presented in Figure 3.3 which shows the 
content of the mucosal fluid after 1 h incubations. At the lowest initial 
concentration of PC (1 mM) 63% of PC remained after 1 h. On a molar basis 25 
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Figure 3.1 Changes in PC and citrate content of isolated loops during an in situ 
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Figure 3.2 Appearance of PC in the serosal fluid of everted sacs. Incubations 
were in KHG buffer for a period of 1 h and the data is the total amount of PC 
transferred during that period. Data represents mean + /- SEM. (n = 6) 
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Figure 3.3 The PC and citrate content of mucosal fluid in everted sacs following 
incubations. The values expressed as a percentage are on a molar basis and 
refer to the amount of PC and citrate remaining after 1 h compared to the PC 
present at time zero. Data represents mean + /- SEM. (n= 6) 
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after the 1 h incubation and data from control experiments where sacs were 
incubated in buffer alone indicated that no citrate or PC was found in the 
mucosal fluid after 1 h. Increasing the concentration of PC in the incubation 
fluid resulted in increased proportions (76% for 5 mM and 78% for 15 mM) of 
PC remaining after 1 h. 
The proportion of citrate present in the mucosal fluid after incubations, 
decreased as the concentration of PC in the initial incubation buffer increased. 
Incubation with 5mM PC resulted in 13% (16.7 pmol) of the initial PC being 
found as citrate after 1 h. Incubation with 15 mM PC showed 9% (33.9 pmol) 
citrate after 1 h. This corresponded to 256 nmol citrate/ pmol PC/ h appearing 
during the 1 mM PC incubation and 134 and 90 nmol citrate / pmol PC / h 
respectively for the 5 and 15 mM PC incubations. Additionally the 
disappearance of mucosal PC and appearance of mucosal citrate was examined 
with respect to time using 5 mM PC incubations. The results (Figure 3.4) 
showed that the concentration of PC decreased in a linear fashion whilst at the 
same time the citrate concentration increased linearly. 
3.4 	DISCUSSION 
Data which emerged from the in situ investigations indicated that PC was 
taken up from the rat intestine. The disappearance was initially rapid but 
slowed as the amount of PC within the loop decreased. This could have been a 
function of the amount of PC available at the gut surface for transfer. Limited 
amounts of citrate also accumulated in loops thus indicating that some 
metabolism of PC to citrate probably occurred. However the extent of 
intralumenal metabolism of PC could not be determined as it was not feasible 
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Figure 3.4 Changes in the concentration of PC and citrate in the mucosal fluid 
of everted sacs during incubations. The initial incubation medium contained 5 
mM PC. Data represents mean +/- SEM. (n=3) 
Studies with the everted sac model confirmed PC transfer across the 
mucosal barrier. However as opposed to the minimal amounts of citrate 
observed intralumenally with the in situ technique, large amounts of citrate 
readily accumulated in the mucosal fluid during everted sac incubations. This 
accumulation appeared to be rate limiting as the amount of citrate as a 
proportion of the initial amount of PC present decreased with increasing 
incubation concentrations of PC. One possible explanation for this decrease is 
that enzyme sites available for the hydrolysis of PC were partially saturated. 
Compared to the amount of PC that disappeared from the in situ lumen 
preparation, only minimal amounts of PC were found to appear in the serosal 
fluid of everted sacs. The viability of the everted sac preparations was confirmed 
by comparing data for citrate transport to that previously obtained by Browne et 
al. (1977). Incubations with 1 mM citrate showed a comparable rate of serosal 
citrate accumulation to that obtained by the earlier study. 
The apparent differences between the two methods may be explained by 
consideration of the nature of the two techniques. Physiologically, the 
absorption process is quite complex and ultimately depends on an intact 
circulation. The everted sac method is an in vitro technique and hence lacks the 
microcirculation which would normally remove absorbed substances. 
Compounds must pass through the epithelial cell layer, the submucosa, external 
muscle layers and serosal tissue of the gut wall before entering the artificially 
created serosal chamber. This may also explain why only limited transfer to 
serosal fluid was observed using the everted sac model. McElnay et al. (1986) 
studied five drug absorption models including everted sacs and found that this 
model demonstrated comparatively small absorption of test compounds. 
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Concerning metabolism of PC to citrate, both techniques used here 
provide some evidence of potential first-pass effects. The accumulation of 
citrate in the lumen of in situ loops though minimal was nevertheless suggestive 
of intralumenal metabolism. However it is possible that citrate reenters the 
lumen following absorption and metabolism of PC intracellularly. Regarding 
the everted sacs, some authors (Gibaldi and Grundhofer, 1972; Levine et al., 
1970) have claimed that everted sac preparations can lose structural integrity 
during the timecourse of an experiment. This loss of integrity, which is inherent 
in the method, may result in the release of hydrolytic enzymes which would not 
otherwise have been able to effect PC. 
Summarising, both techniques indicated that PC was removed from the 
gut lumen. Further to this PC was found in the serosal fluid of everted sacs thus 
demonstrating actual transfer. Also an examination of the everted sac data 
showed that a stead); accumulation of citrate occurred and thus revealed the 
possibility of a first pass effect. To further understand the absorption process, 
other more detailed investigations need to be instigated. Certainly, the 
appearance of PC in the circulation following uptake from the lumen would be 
indicative of some transport occurring and is therefore an important aspect. 
Hepatic-portal sampling during an intestinal perfusion may help provide 
additional data for understanding the problems associated with PC uptake. 
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CHAPTER 4 
FURTHER INVESTIGATIONS CONCERNING PC BIOAVAILABILIT'Y 
4.1 	INTRODUCTION 
Physiologically the absorption process is controlled by the nature of the 
epithelial barrier but is finally dependant on blood and lymph flow away from 
the intestine. Barr and Riegelman (1970) have defined absorption as the 
amount of unchanged drug absorbed from the intestinal lumen which appears in 
the portal circulation or intestinal lymph. Clearly the microcirculation of the 
intestinal mucosa (Figure 4.1), containing a comparatively high capillary density, 
is complex and an integral part of the absorption process (Granger et al., 1987). 
Hence the most revealing studies concerning absorption might be those carried 
out under experimental conditions which maintain the functionality of the 
circulatory system and allow sampling from the hepatic portal circulation. 
Data from the calcergy studies, in situ ligated loop and everted sac 
experiments all suggested that some PC absorption occurred. Additionally, the 
latter two techniques provided evidence that possible metabolism to citrate 
might limit the available PC. Hence the results of the previous experiments 
portrayed two aspects to be considered. Firstly, can transfer of PC across the gut 
epithelia be demonstrated in vivo and secondly, is there significant metabolism 
of PC, either intralumenally or during passage across the intestine? To answer 
these and other questions relating to PC absorption, additional experiments 
which consider the appearance of PC in the portal vein could be informative. 
A variety of intestinal perfusion models are reported in the literature 
















(Crypts of Lieberkiihn) 
Villus Subepithelial 
Capillary Network 
Figure 4.1 Model of mtkosal microcifcUlation typical of human- and rabbit small 
intestine. VV, villus venule; VA, villus arteriole; solid arrows indicate direction 
of blood flow; open arrows indicate directions of secretion and absorption of 
intestinal fluid. (reproduced from Granger eta, 1987). 
for absorption studies. Recently Yorgey et al. (1986) and Blanchard et al. (1990) 
have utilised this technique with venous cannulation for studying drug 
absorption. Techniques for sampling of blood and lymph following oral 
administration are also well established (Gallo- Torres and Ludorf, 1974; 
Charman, 1986). The studies reported here use a perfused loop concurrent with 
portal vein cannulation. Basically the technique is a more elaborate version of 
the in situ loops described by Levine and Pelikan (1961). Two L-shaped 
cannulae are surgically inserted at either end of a section of intestine and then 
connected to syringes allowing multiple sampling of the intestinal contents. 
Additionally, the potential therapeutic effect of a drug is dependant on 
the bioavailability and the rate of disappearance or elimination from the 
systemic circulation. Hence further experiments were devised to gain insight 
into the nature of the reduced bioavailability of PC following oral 
administration. These involved measuring the disappearance of PC from the 
bloodstream following an intravenous bolus of PC. When taken together, the 
data measuring absorption from the lumen, the appearance of PC in the portal 
vein and the intravenous disappearance of PC should provide useful 
information concerning PC absorption, first-pass effects and elimination. This 
should allow decisions to be made concerning research directions for the 
development of an appropriate dosage form of PC. 
4.2 	METHODS 
4.2.1 	Equipment and Reagents 
General equipment used included a liquid scintillation counter 
(Beckman), water bath heater pump (Techne TE7), temperature controlled 
oven (Townsen), and centrifuges (Sorvall RC2-B, Eppendorf 5414S, IEC. DPR- 
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6000). 1,5- 14C- Citrate was obtained from DuPont (NEN research products, 
Boston, MA.). 
	
4.2.2 	Synthesis of radioactive PC 
Typically, 1,5- 14C-citrate (250-750 pCi) was combined with 10 mg of cold 
citrate and methylated with diazomethane according to the method of Hudlicky 
(1980). Solvent was removed by rotary evaporation and the resulting 1,5- 14C-
trimethyl citrate stored in a vacuum dessicator prior to use. For synthesis, the 
1,5- 14C-trimethyl citrate was added to a small vial containing unlabelled 
trimethyl (or triethyl) citrate (total 1 mmol) and 3 ml of a benzene/pyridine 
mixture (0.54 ml pyridine/ 15 ml benzene). 0-phenylene phosphorochloridate 
(1 mmol) dissolved in 3 ml benzene was then added dropwise to the vial and the 
synthesis and isolation of products then proceeded according to the description 
in section 2.2.2 with appropriate small scale modifications. 
Characterisation of 14C-PC included TLC on cellulose plates in a solvent 
system comprising isobutyric acid/ 5.5% ammonia (w/w)/ methanol (60:40:100. 
v/v) In this system the Rfs of citrate and PC are 0.42 and 0.20 respectively. The 
location of radioactive material was detected using a spark chamber (Birchover 
Instruments, Herts., England) and photographic detector (polaroid, film type 
87). 14C-PC was also analysed using the method described in section 3.2.2. 
4.2.3 	Intestinal Cannulation 
The cannulation procedure was according to the method of Doluisio et . 
al. (1969). Male Hooded Wistar rats weighing 240-260 g were fasted overnight 
and the following morning anaesthetised with an intraperitoneal injection of 
sodium pentobarbitol (200 All, 60 mg/ml diluted 1:1 with saline). The 
gastrointestinal tract was exposed with a midline abdominal incision. A section 
of intestine starting approximately 5 cm posterior to the pyloric sphincter and 
usually 30 cm in length was isolated. Small incisions were made at the proximal 
and distal ends of this section and two L-shaped glass cannulae were inserted. 
The cannulae were secured with silk ligatures and the intestines then returned 
to the abdominal cavity in a way that left only the cannulae exposed. Glass 
hypodermic syringes (20 ml) were connected to the cannulae with latex tubing 
(I.D. 1/32", O.D. 1/8"). The abdominal opening was then covered with a saline 
moistened (37°C) gauze. A layer of thin plastic sheeting ("Gladwrap") was 
placed over the gauze. If portal vein cannulation was required, then this surgery 
was always performed prior to the intestinal procedure. 
4.2.4 	Portal Vein Cannulation 
A technique similar to that described by Davison (1989), which involved 
introducing a free floating cannula into the portal vein, was used. The vein was 
exposed and surrounding adventitious tissue cleared away. Curved forceps were 
used to hold the vein away from the body wall while two loose ligatures were 
placed under the vein about 1 cm apart. Correct manipulation resulted in an 
isolated 1 cm section of vein engorged with blood. This facilitated the 
cannulation step which involved making a small puncture in the vein with a 19 
gauge hypodermic needle followed by rapid insertion of the cannula (PE 50, I.D 
0.50 mm, O.D. 1.00 mm) and release of the ligatures. The end of the cannula 
was bevelled to facilitate entry into the vein and inserted to a depth of 1.0 cm 
towards the liver. The cannula was secured by suturing in two places to the 
abdominal wall. 
Clotting was prevented by first filling the cannula with heparin (David 
Bull Labs., Aust., porcine sodium heparin, 1000 units / ml) and inserting a small 
plug in the free end. Before sampling, the heparin was withdrawn together with 
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a small volume of blood and a fresh syringe was connected. 
4.2.5 	Vena cava cannulation and perfusion 
Cannulation was according to Kaufman (1980). The vena cava was 
exposed by moving the abdominal contents to one side and dissecting away 
surrounding fat and connective tissue. The cannulation step was similar to that 
described above for the portal vein cannulation. Silk ligatures were positioned 
in place 1.0 cm apart. The vein was punctured 1.0 cm above the ileac bifurcation 
and a heparin filled cannula (PE 50) with a bevelled end inserted to a depth of 
1.0 cm. 
For perfusions, a solution containing 1,5- 14C-PC (195 Al) was 
introduced into the vena cava as a bolus containing 5 mg of PC. The specific 
activity of the radioactive preparation was 1.738 x 106 cpm/mg PC. 
4.2.6 Intestinal Perfusion 
Isotonic saline was slowly perfused for a period of 5 min, followed by 
Krebs - Henseleit (Dawson, 1986, p446) buffer for a further 15 min. The 
experiment was then commenced by introducing Krebs - Henseleit buffer 
containing an appropriate concentration of PC. Solutions were maintained at 
37°C and Krebs - Henseleit buffer was equilibrated with 5% CO2 / 95% 02 
prior to perfusion. Sampling was conducted at time intervals during the 
experiment by expelling the perfusate into one of the syringes using air pressure 
derived from the other syringe. This procedure resulted in adequate mixing of 
the perfusate before sampling and a short time interval between expulsion and 
returning the perfusate to the intestine. Manipulation and disconnection of the 
syringes was made possible by pinching the tubing which joined the cannula to 
the syringe. Maintenance of body temperature was facilitated by using a heating 
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lamp and heating pad. Perfusate volumes were recorded at each sampling as the 
syringes were calibrated for volume determination. 
Perfusions were initiated by introducing the perfusion medium and 
immediately taking an aliquot of the perfusate. This was defined as the zero 
time sample. The perfusion arrangement is shown in Figure 4.2. 
4.2.7 	Chromatography 
4.2.7.1 	Treatment of Blood Samples 
The procedure was conducted at 4 °C and prior to use, reagents were 
kept on ice. Extraction involved adding perchloric acid (1 M, 600 pl) to whole 
blood (300 /.1l) and mixing vigorously. After 2 min on ice, the acid extract was 
centrifuged (Eppendorf, 2 min, 8000g, 4 °C) and the supernatant transferred to 
another tube containing one drop of phenol red indicator (BDH chemicals, 
0.02%). Potassium carbonate (2 M) was added dropwise until neutrality was 
indicated. The resulting mixture was then centrifuged (Eppendorf, 2 min, 8000g, 
4°C) and the supernatants lyophilised. Larger volumes were treated in a similar 
manner with appropriate volume changes and centriftigation in a Sorvall 
centrifuge (RC2B, 10,000g, 4 °C). 
4.2.7.2 	Chromatographic analysis of Extracts 
Lyophilised samples were reconstituted in a minimum volume and 
applied to Whatman No. 1 chromatography paper as a thin band 10 cm long. 
Several applications were required allowing the paper to dry between 
applications so that maximum loading was achieved. The paper was then 
developed by descending chromatography (2.5 h) in a solvent system comprising 
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Figure 4.2 Perfusion system used for measuring intestinal absorption. (based on 
Doluisio et. aL, 1969) 
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n-propanol/ water/ glacial acetic acid (4:1:1. v/v) 
After the designated running time the chromatograms were cut into 
strips (0.5-1.0 cm) parallel to the aplication band and then subsequently cut into 
smaller pieces and packed into 2.5 ml plastic syringes. The contents on the 
paper were extracted twice with 1 M HC1 (0.5 ml). During each extraction the 
packed strips were allowed to soak in HC1 for 5 min before centrifugation (1000 
g, 5 min) directly into plastic scintillation vials for counting. A rubber grommet 
allowed the syringe to fit tightly over the vial during centrifugation. 
4.2.8 	Digestion and counting of Blood Samples 
Blood samples were processed as described by Williams (1981). The 
procedure ensured efficient recovery of the radiolabelled compounds with 
digestion achieved by the addition of an oxidative mixture comprising perchloric 
acid (70% w/v, 200 ml) and hydrogen peroxide (30% w/w, 400 /11) in a glass 
counting vial. The vials, fitted with acid resistant caps, were heated (50-60°C) 
until the solutions turned colourless. This process usually took 1-2 h after which 
the vials were allowed to cool to room temperature before the addition of 
scintillant (10 ml) and counting. The scintillant (Fricke, 1975) was an acid 
resistant cocktail composed of 3.0 g PPO (2,5-diphenyloxazole), 257 ml Triton 
X-100, 106 ml Ethanol, 37 ml Ethylene glycol and 600 ml Xylene. 
4.3 	RESULTS 
4.3.1 	Intestinal perfusion of PC 
Absorption of 1,5- 14C-PC was measured following in vivo perfusion with 
5 mM PC. Figure 4.3 (A) and (B) show the disappearance of PC from the lumen 
as determined by enzymatic assay for PC (A) and the disappearance of total 
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radioactivity (B). Figure 4.3 (A) indicates an absorption rate of 16 mg (36 
pmol)/ 30 cm intestine/ h. This corresponded to 53% of the PC present at time 
zero. Figure 4.3 (B) indicates that 55 % of the total radioactivity present at time 
zero disappeared in 1 h. Additionally, the uptake of radioactivity by portal blood 
during four individual experiments was measured (Figure 4.4). In all profiles, 
radioactivity increased with time and in one experiment a plateau of absorption 
was reached. The presence of PC in portal blood was determined by 
chromatographic analysis and is shown in Figure 4.5. The data revealed limited 
absorption at 15 and 30 min but the 45 and 60 min samples did indicate the 
presence of PC in portal blood. At each time point the presence of radioactive 
citrate was also apparent from the chromatographic profiles. Radioactive 
material which did not correspond to standard PC or citrate, was also noted in 
the profiles. 
The possibility of PC absorption being related to a tricarboxylic acid 
carrier was briefly explored by conducting some experiments which included a 
transport inhibitor. Figure 4.6 shows that the presence of 2.5 mM tricarballylate, 
a tricarboxylic acid transport inhibitor (Browne et al., 1978), in the perfusion 
medium did not affect the uptake of PC. However there was an indication of 
increased citrate accumulation in the intestinal lumen. 
4.3.2 	Disappearance of PC following I.V. administration 
Figure 4.7 shows the non-linear disappearance of 1,5- 14C-PC from the 
circulation following an intravenous bolus. At 1 min the radioactivity in blood 
was 12,099 cpm/200 pl. On the basis of an average total blood volume of the rat 
being 64.1 ml/kg (Altman and Dittmer, 1974) this corresponded to 11.1% of the 
total counts administered. Chromatographic analysis (Figure 4.8) indicated that 
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Figure 4.3 Disappearance of PC from intestinal perfusate. 
A: Data measured as total PC by enzymatic assay. B: Data measured as 
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• Figure 4.4 The appearance of radioactivity in portal blood during intestinal 
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Figure 4.5 The pattern of radioactivity appearance in portal blood during 
intestinal perfusions. Protein free extracts were chromatographed. 
Chromatograms were divided into 1.0 cm strips for determination of 
radioactivity. The presented data is from a single experiment. However the 
studies were repeated on three other occasions. 
1:=3 5 mM PC (n=5) 
CM 5 mM PC + 2.5 mM Tricarballylate (n=3) 
NM Free Citrate 




Figure 4.6 The effect of tricarballylate on the uptake of PC from the intestinal 
lumen. Total citrate as determined by in vitro assay of recovered samples 
(section 3.2.2) refers to hydrolysable PC plus free citrate. Data represents mean 
+ /- SD. 
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Figure 4.7 Disappearance of radioactivity from the blood stream following 
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Figure 4.8 Chromatographic analysis for radioactivity in systemic blood samples 
following an intravenous bolus of 1,5- 14C-PC. The data was obtained as for 
figure 4.5. 
the radioactivity was present mostly as PC. At 5 min radioactivity was reduced 
to 5941 cpm/200 Al whilst at 15 and 60 min, the radioactivity was 3505 and 1372 
cpm/200 Al respectively. The chromatographic profiles for these time intervals 
indicated that a decreasing proportion of the counts was due to PC. 
4.4 	DISCUSSION 
Radiolabelled PC was used to demonstrate transport across the 
gastrointestinal tract. Absorption of PC from the lumen was clearly established. 
Disappearance of radioactivity matched the uptake of PC, as was determined by 
assay for PC. This data is in line with the information obtained in the previous 
chapter. Further information regarding absorption was also obtained following 
analysis of portal blood samples. The data provided conclusive evidence that PC 
was appearing in the portal vein following lumen perfusion. This was 
anticipated as previously, partial inhibition of calcergy was observed following 
oral delivery of PC. Chromatographic data indicated that radiolabelled citrate 
also appeared in the portal vein which was suggestive of the possibility of first-
pass metabolism of PC in intestinal tissue. 
However, although the chromatographic data suggested that more citrate 
was appearing in the portal circulation than PC, if citrate was absorbed at a 
faster rate than PC this pattern might result even if metabolism was not a 
limiting factor. Citrate is believed to be absorbed by a specific mechanism 
(Browne et al., 1978; Wolffram et al., 1990). Therefore if PC is absorbed by a 
restricted passive process, then it is possible that the citrate which appeared in 
the portal vein was a higher proportion of the total radiolabelled citrate than 
was the case for PC. In support of this, the appearance of PC in portal blood 
was not apparent until at least 45 min into the perfusion. In addition, the 
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chromatographic profiles of portal blood indicated that citrate appeared at an 
earlier time-point than PC during the perfusion. 
Having established that PC appeared in the portal vein and that some 
gut metabolism had occurred, some future consideration might also need to be 
given to the role of the liver in any discussion of first pass metabolism. Although 
results obtained by Williams (1981) showed that the liver did not accumulate 
large amounts of radioactivity following intravenous injection of labelled PC, 
nevertheless, this organ may still influence the ultimate systemic concentrations 
reached following oral delivery of PC. 
Also there is a need to further quantitate the actual rate of PC 
absorption and metabolism. Techniques which may aid this process include 
using a total mesenteric collection or complete vascular perfusion (Windmueller 
and Spaeth, 1984). Such techniques however could be applied best if a highly 
sensitive assay for PC was available. The current absence of a very high specific 
activity ity preparation or an ultra sensitive assay for unlabelled PC in 
blood, limited the overall detection and quantitation of PC. This was further 
complicated by the rapid disappearance of PC from the systemic circulation 
which meant that concentrations of radioactive PC and metabolites in blood 
were reduced to levels which were at the detection limits of the analytical 
sysyem used. 
Another aspect to PC absorption was the investigation of the transport 
mechanism with regard to localisation within the intestine. Although this area 
does not fall completely within the brief of the current study, some preliminary 
experiments were instigated and it was found that PC disappeared from the 
intestinal lumen throughout the length of the intestine. Further studies which 
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measure the appearance of PC in the portal vein following perfusion of various 
intestinal segments could also be helpful especially in regard to metabolic 
events taking place. Enzyme activity is known to vary considerably throughout 
the length of the intestine (Weiser et al., 1986). 
Preliminary studies concerning the mechanism of PC uptake were 
initiated using tricarballylate, an inhibitor of tricarboxylic acid transport. 
Generally, the data obtained (this chapter and everted sacs) indicated that PC 
absorption was slow and possibly via a passive process as opposed to an active 
or facilitated transport mechanism. That tricarballylate did not alter the 
absorption profile of PC may also be suggestive that uptake is not via a known 
active process. Marginally increased levels of citrate within the lumen were 
apparent indicating that some inhibition of citrate uptake may have occurred. 
The disappearance of PC from the systemic circulation following an 
intravenous bolus is relevant to the issue of gut absorption. The data indicates 
that greater than 90% of injected PC disappeared from the circulation within 1 
min. This rapid rate of disappearance of PC from the blood coupled with its 
slow absorption from the intestine might combine to render PC less effective 
orally than by intraperitoneal injection. Perhaps then PC, following oral 
administration, does not reach threshold levels necessary for the effective 
prevention of calcergy formation observed following intraperitoneal 
administration. 
Chromatographic studies showed that the proportion of radioactivity 
attributable to PC, following the administration of an intravenous bolus, 
decreased in time with citrate appearing as the main metabolite. This indicated 
that some PC does undergo metabolism after entering the systemic circulation. 
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It is not clear whether the appearance of radioactive metabolites is due to 
enzymic activity in blood or follows the release from tissue after uptake and 
breakdown of PC. 
Overall, the data obtained in this study so far has indicated that PC was 
absorbed and was active following oral delivery of the compound. However the 
need for improved forms of the compound for oral administration is clear. 
Prodrugs have been used for many drug compounds when carboxylic acid 
functional groups complicate the absorption process (Waller and George, 1989) 
making it a possible approach for increasing the systemic availability of PC 
following oral delivery. 
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CHAPTER 5 
SYNTHESIS AND ANTICALCIFYING POTENTIAL OF PC ESTERS 
5.1 	INTRODUCTION 
The poor bioavailability of PC following oral delivery would appear to be 
a property of its physical characteristics. Whilst the high charge to size ratio and 
stereochemistry of the molecule is clearly essential to its inhibitory power it is 
obviously not conducive to efficient uptake of the compound from the gut. The 
data suggests that to improve its transport efficiency across membranes, a 
strategy is needed which can deliver PC intact to the appropriate tissue 
following oral delivery. 
Generally, the bioavailability of a drug can be improved by physical, 
biological or chemical means (Sinkula and Yalkowsky, 1975). The physical 
approach primarily involves manipulation of the dosage form to achieve a 
maximum response. The biological approach involves variation in the route of 
administration. However this strategy is often limited due to the inconvenience 
of many administration routes. Clinically the oral route is preferred and 
problems concerning absorption may need to be directly overcome. For this 
reason the chemical approach is sometimes the most useful avenue to improved 
bioavailability. 
Chemically, two options are available: (i) Synthesise a chemical analog 
which would be expected to differ from the original in efficacy and a range of 
other pharmaceutical parameters (Sinkula, 1982). However the essential 
bioactivity of the parent compound would have to be retained. (ii) Develop a 
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prodrug by chemically altering a known drug to form an inert molecule which 
following administration would undergo biotransformation to yield the active 
compound and an inert pro-moiety (Figure 5.1). A range of derivatisations have 
been used for this purpose ranging from standard chemical linkages including 
amides, esters and phosphates (Notari, 1981) to more novel approaches such as 
the synthesis of methylthiomethyl derivatives of carboxylic acids (Bodor, 1982). 
The type of chemical modification actually required needs to be considered in 
light of reactive functional groups on the parent molecule and on the availability 
of in vivo systems for bioactivation of the prodrug. In respect to the latter, a 
range of enzymes have been used, including esterases, amidases, phosphatases 
and reductases (Sinkula and Yalkowsky, 1975). 
Prodrugs have been used to aid a range of pharmaceutical problems 
including improvement of taste, decreasing dangerous side effects, decreasing 
gastro-intestinal irritation, increasing solubility and obtaining site specificity 
(Notari, 1981). Another factor commonly overcome using the prodnig approach 
is the oral absorption of water soluble and highly polar compounds. 
Derivatisation with lipophilic groups has been used in many instances to 
overcome their limited absorption. More specifically, esterification with a 
hydrophobic moiety will often improve the absorption of a drug containing a 
carboxylate functional group (Sinkula and Yalkowsky, 1975), two notable 
examples being ampicillin (Clayton et al., 1976) and carbenicillin (Clayton et al., 
1975). 
Therefore the development of a prodrug form of PC was envisaged as a 
tool to increase its transport across the gut. Accordingly, the use of alkyl esters 
of PC was considered as (1) the proposed compounds should have increased 







      
      
Barrier to usefulness 








Figure 5.1 The prodrug concept (reproduced from Waller and George, 1989) 
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lipophilicity and (2) such compounds should be converted back to active PC as a 
range of enzymes able to hydrolyse short to medium chain aliphatic ester 
derivatives exist (Sinkula and Yalkowsky, 1975). These include cholinesterases, 
carboxylesterases, acetyl esterases and lipases. Carboxylesterases (Krisch, 1971), 
which could be considered the most likely enzyme group to hydrolyse the ester 
bonds of PC alkyl esters, are commonly found in high activity in liver, 
duodenum, kidney and brain (Waller and George, 1989). The possibility that 
esterification might reduce any first-pass effects through steric inhibition of 
enzymic or chemical hydrolysis of PC might also be an advantage. 
The availability of phosphotriethyl citrate (PTEC) as an impure 
intermediate in the synthesis of PC (section 2.2.2) provides a starting point 
regarding synthetic possibilities. If a suitable synthetic strategy could be 
developed then the potential for a prodrug compound of PC to undergo 
hydrolysis and release active PC into the systemic circulation would need to be 
tested. In this respect it was envisaged that the previously established calcergy 
model (section 2 2.2) would again be suitable. 
5.2 	EXPERIMENTAL 
5.2.1 	Synthesis of phosphotriethyl citrate 
The reaction mixture obtained following the first step in the synthesis of 
PC (section 2.2.2) was dissolved in CH2C12 and applied to a silica column (I.D. 
1.4 cm x 25 cm) pre-equilibrated with CH2C12. The column was initially eluted 
with CH2C12 (150 ml) after which the eluting solvent was changed to 2% 
Me0H in CH2C12. The first 50 ml of eluant was discarded and thereafter 
fractions (5 ml) were collected. The progress of separation was monitored by 
TLC. Fractions which contained the coupled product (triethylcitrate coupled to 
o-phenylene phosphochloridate) were combined and hydrogenated (section 
2.2.2). Following hydrogenation the mixture was neutralised (NaOH, 1M), 
rotary evaporated, extracted into CH2C12 and rotary evaporated again resulting 
in a white crystalline material with a typical ester aroma. 
5.2.2 	Partial synthesis of phosphotrioctyl citrate 
The planned strategy for the synthesis of phosphotrioctyl citrate required 
the initial synthesis of trioctyl citrate, subsequent phosphorylation, followed by 
isolation and purification. Accordingly trioctylcitrate was synthesised from 
citrate as described by Pelister and Breusch (1976) for the esterification of 
propene-1,2,3-tricarboxylic acids. Citrate (25 rrunol) and octanol (82.5 mmol) 
were added to a 100 ml round bottom flask together with 481 mg of p-toluene 
sulphonic acid (5% of citrate weight) in 50 ml of toluene. A calibrated trap for 
water collection and a reflux condensor was fitted and the reaction proceeded 
under reflux for 2-3 h or until the evolution of water discontinued. The mixture 
was washed with water (3x50 ml), 5% KHCO3 (2x50 ml) and finally with 50 ml 
water before drying over sodium sulphate. The drying agent was removed by 
filtration and the toluene by rotary evaporation. Trioctyl citrate was crystallised 
at -20°C from a minimum volume of toluene, washed with ethanol and 
recrystallised from ethanol (x2) at - 20 °C. 
Trials were conducted to investigate the possibility of synthesising 
phosphotrioctyl citrate by phosphorylation with o-phenylene phosphochloridate 
and hydrogenation using identical techniques to those described for the 
synthesis of phosphotriethyl citrate (section 5.2.1). 
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5.2.3 	Monoester synthesis 
5.2.3.1 	Preparation of polymer linked AlC13 
Polymer linked A1C13 was prepared according to the method of Neckers 
et a/. (1972). Accordingly, 15.5 g of polystyrene-divinyl-benzenecopolymer beads 
(3.5%, 50-100 mesh, Sigma) was combined with carbon disulfide (225 ml) and 
aluminium chloride (3.75 g, anhydrous) in a 3-neck 11 flask equipped with a 
mechanical stirrer, condenser and dropping funnel. The mixture was stirred 
under reflux for 40 min, then cooled before the addition of water (200 m1). The 
beads were filtered and washed successively with 11 of water and 150 ml each of 
ether, acetone, hot isopropanol and ether. 
5.2.3.2 	Synthetic trials using PC -bead combinations 
Various combinations of polymer• beads, PC and alcohols were used in 
the exploration of monoester synthesis. The following description represents a 
typical preparation: Free PC was prepared by removing sodium from the usually 
available sodium salt. Accordingly, PC (45 mg) was dissolved in water (500 pl) 
and applied to a small column (15x8 mm) of AG.50W-X8 in the H + form. The 
PC was collected in the second 500 pl of eluate and n-butanol (740 pl), polymer-
A1C13 beads (100 mg) and benzene (500 Al) were then added. The mixture was 
heated at 80°C with shaking for 3 h before filtering, evaporating to dryness 
under a stream of N2. Trials varied and involved using butanol, propanol and 
ethanol under conditions which varied in temperature from 50- 80°C. 
5.2.3.3 	Monoesters from hydrolysis of PTEC 
PTEC preparations were subjected to various hydrolytic conditions 
involving differences in temperature (0-80°C) and base content after which the 
solutions were neutralised (HC1, 1 M) and freeze dried. Primarily two types of 
alkali, sodium and strontium hydroxide, were used and the quantities varied 
from a one third molar equivalent of PTEC to a large excess. Sometimes the 
method of Meyer et al. (1959) was used. 
5.2.4 	General assays 
PC, citrate and phosphate analyses were performed by previously 
described methods (section 3.2.3). Ethanol was determined according to the 
method described by Bernt and Gutmann (1974). 
5.2.5 	Chromatographic procedures 
5.2.5.1 	Gas chromatography (GC) 
A Hewlett Packard (model 5890A) gas chromatograph fitted with a 
poropak Q column (80-100 mesh, Waters assoc. inc. Mass. USA), and a flame 
ionisation detector linked to a Shimadzu printer/analyser (model C-R3A, 
Kyoto, Japan) was used. Samples were dissolved in CS2 and injected (5-10 ul). 
The operating conditions were: injection port 1800C; oven temperature 250°C; 
detection temperature 200°C and the carrier gas was nitrogen. 
5.2.5.2 	Thin layer chromatography (TLC) 
Fractions obtained in the synthesis of PTEC were analysed by TLC, 
which was performed on either silica gel or cellulose coated plates. Aluminium 
sheets precoated with silica gel 60 F254 (Merck, 0.2 mm thickness) were used. 
For cellulose chromatography, glass plates were coated with Sigmacell (type 20) 
to a thickness of 0.25 mm, dried and stored prior to use. The solvent system for 
silica TLC was CHC13/Me0H (80:20) whereas for chromatography on the 
cellulose plates the solvent systems were either isobutyric acid: 5.5% ammonia: 
methanol (66:40:100) or eucalyptol: n-propanol: formate: water (50:50:20:10). 
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For the analysis of products obtained in the synthesis of phosphotrioctyl 
citrate, several solvent systems were trialled. Ultimately, the two most 
satisfactory were (a) isobutanol: isopropanol: ethanol: water: 25% ammonia 
(25:20:34:0.7:10) and (b) chloroform: ethanol: water: triethylamine (30:34:8:35) 
5.2.6 	High voltage electrophoresis (HVE) 
Some samples were identified following separation by paper HVE 
(Equipment purchased from Paton Industries Pty. Ltd., Beaumont, S. Aust.). 
The electrophoresis was performed on Whatman 3MM paper at 2000 v for 1.5 h 
using 0.05 M triethanolamine bicarbonate buffer, pH 7.5. 
Samples which had been subjected to hydrolysis (section 5.2.3.3) were 
subsequently prepared for analysis by HVE. The hydrolysates were vacuum 
dried and the resulting lyophilisates were dissolved in 1 ml of water before 
application to a cation exchange column (AG.50W-X8, H + form) (I.D. 0.45 cm 
x 4 cm). The column was eluted with 1 ml of water and the eluants were 
combined. Samples (5 ul) were applied to paper for analysis. 
5.2.7 	Visualisation techniques 
5.2.7.1 	Organic acids and phosphates 
Organic acids and phosphates were detected according to the method of 
Firmin and Gray (1974) which required the following reagents: 
Solution A: 1.1% Ammonium thiocyanate in acetone 
Solution B: 0.03% FeC13.6H20 in acetone 
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Electrophoretograms were dipped briefly in solution A and air dried for 5 min 
at room temperature before dipping in solution B and again air drying. Organic 
acids and phosphates showed as bleached white stains on a reddish brown 
background. 
	
5.2.7.2 	Phosphate specific stains 
Two general phosphate detection stains were used: 
(a) Molybdenum blue visualisation reagent (Maile et al., 1977). 
Solution 1: 11 of 25 N H2504 and 40.11 g of Mo03 were mixed and gently 
boiled until the Mo03 was dissolved (3-4 h). The solution was allowed to cool at 
room temperature overnight. 
Solution 2: Powdered molybdenum (1.78 g) was dissolved in 500 ml of solution 1 
by boiling gently for 15 min before cooling and decanting to separate any 
remaining residue. 
Working reagent: Equal volumes of solutions 1 and 2 were added to 4.5 vol. of 
water to form a green solution which was sprayed onto plates and paper 
electrophoretograms. Phosphate containing compounds were visualised as blue 
spots. 
(b) Ammonium Molybdate-Perchlorate (Dawson et al., 1986) 
The reagent which comprised 60% w/v perchloric acid: M-HC1: 4% ammonium 
molybdate: water (5:10:25:60) was sprayed onto chromatography plates which 
were then heated at 85°C for 1 min. Free phosphate was visualised as a yellow-
green spot and unhydrolysed phosphoric esters as blue spots. 
5.2.7.3 	Detection of octyl containing compounds - Iodine vapour 
Chromatograms were developed by placing in a tank containing iodine 
crystals. Iodine absorbing compounds were revealed as brown to yellow spots on 
a faint yellow background. 
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5.2.7.4 	Ultra-violet visualisation of chromatograms 
Chromatograms were viewed under an ultra-violet lamp (254 nm). Ultra-
violet absorbing compounds appeared as darkened regions on the 
chromatogram. 
5.2.8 	Calcergy studies with PTEC 
The inhibitory power of PTEC was tested using the calcergy model 
described in chapter 2. The compound was administered as a solution in water, 
by gavage, intraperitoneal or subcutaneous injection at a dose level of 50 
mg/kg/day. 
5.3 	RESULTS AND DISCUSSION 
5.3.1 	Synthesis, isolation and characterisation of PTEC. 
Of the various chromatographic media which were trialled in order to 
effect the separation of PTEC, preparative silica column chromatography prior 
to hydrogenation was found to give the best separation. Figure 5.2 shows a 
typical TLC analysis of fractions obtained during this procedure. The middle 
spot (Rf = 0.4), identified as containing PTEC, increased in size and intensity as 
compared to the top spot (Rf = 0.7). 
PTEC was characterised by HVE, 1H-NMR, and analysis for free and 
hydrolysable phosphate. Figure 5.3 shows that under HVE there was a major 
spot with a relative mobility (R.M.) compared to Pi of 0.50. Two minor spots 
were also apparent on the chromatogram (R.M.'s 1.00 and 0.64). Whilst the 
uppermost spot corresponded to the position of free phosphate, the other small 





Figure 5.2 TLC of preparative silica column fractions. The fractions were 
obtained from separation of a triethyl citrate phosphorylation mixture. The 
separation medium was silica and the solvent system used was CHC13/Me0H 
(80:20 v/v). - very intense ea - mildly intense o - weak staining 
+ve 
Pi 	PC 	PTEC 
80 
origin 
Figure 5.3 High voltage paper electrophoresis of phosphate (Pi), phosphocitrate 
(PC), and phosphotriethyl citrate (PTEC). The relative mobilities compared to 
phosphate are 0.78 for PC and 0.50 for PTEC. - very intense ea - mildly 
intense Di - weak staining. 
spot was unidentified. PC and inorganic phosphate were included on the 
chromatogram for reference. 
The 1H-NMR spectra is presented in Figure 5.4 and the data indicated 
that PTEC was successfully synthesised but that TEC was present as a 
contaminant in the preparation . The characterisation of PTEC was supported 
by analysis for free and hydrolysable phosphate in the mixture. Whilst the 
presence of free phosphate was apparent from examination of 
electrophoretograms, analysis showed that Pi contamination was not significant 
( <1%). Analysis of hydrolysable phosphate indicated that the purest 
preparations contained PTEC in 90-100% of theoretical yield. 
Gas chromatography was also used in the characterisation of PTEC. 
However, the results from GC were not conclusive as separation could not be 
achieved under any of the conditions used. Although PTEC eluted in the same 
position as triethyl citrate, no other peaks were detected. One possible 
explanation for these results is that PTEC is vulnerable to thermal breakdown 
yielding 'TEC and phosphate. 
5.3.2 	Effect of PTEC on calcergy 
Figure 5.5 shows the effect of PTEC on plaque calcification. The 
administration of PTEC by the intraperitoneal and oral routes had no 
significant effect on plaque formation (intraperitoneal, 0.40> p > 0.30; oral, 
p > 0.40). However, when administered subcutaneously at the calcergic site 
PTEC reduced plaque formation by 31% (p <0.0005) compared to the 
subcutaneous injection of isotonic saline. Of interest, the administration of 
saline subcutaneously also reduced plaque formation (15%, 0.01 > p >0.0005) 
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Figure 5.5 Effect of P'TEC on calcergic plaque formation. Data represents mean 
+ /- SEM. (n = 12-16 plaques). 
action is unknown but it is clear that there was no difference between control 
rats which had been dosed with saline via the oral and intraperitoneal routes. 
The minimal inhibition seen when PTEC was administered 
subcutaneously may have been the result of enzymatic cleavage at the site of 
calcergic plaque formation. Although unlikely, an alternate explanation might 
be that trace amounts of PC in the PTEC preparation were responsible for the 
observed reduction in calcergy formation. The presence of PC could not be 
detected by HVE (Figure 5.3). 
Following the failure of PTEC to act in vivo, investigations which 
subjected PTEC to carboxylesterase action in vitro were initiated. The data is 
not shown here because the results proved entirely negative. Ethanol 
production was not observed following incubation of PTEC with 
carboxylesterase, indicating that ester hydrolysis had not occurred under the 
conditions used. 
5.3.3 	Investigation of phosphotrioctyl citrate synthesis 
Characterisation of trioctyl citrate revealed >99% purity by gas 
chromatography. Mass spectrometry (Figure 5.6) was consistent with trioctyl 
citrate and TLC showed a single spot. 
Following phosphorylation of trioctyl citrate, TLC showed a similar 
pattern to that usually obtained with the phosphorylation of triethyl citrate 
(section 2.2.2). Chromatographic separation of phosphotrioctylcitrate from the 
hydrogenated mixture by silica chromatography was explored without success. 







Figure 5.6 Mass spectroscopic analysis of trioctyl citrate 
to medium chain alkyl esters of the type envisaged would not eventually lead to 
active prodrugs of PC. 
5.3.4 	Monoesters of PC 
The inability of PTEC administration to result in inhibition of calcified 
plaque formation led to the notion that monoesters of PC might have prodrug 
potential. Malhotra et al. (1978) has reported that the specificity of 
carboxylesterases can totally prevent hydrolysis of some ester compounds. 
Hence consideration was given to the possibility that in vivo hydrolysis of the p-
ester linkage on PTEC might have been a limiting factor. Additionally, 
Lehninger (1983) has reported that the final ester linkage on PTEC is difficult 
to remove during hydrolysis and Tew et al. (1980) have reported that a 
monoethyl ester of PC did not inhibit the in vitro growth of hydroxyapatite 
crystals. 
Monoester synthesis was found to be possible using the controlled 
hydrolysis conditions described by Meyer et al. (1959). 1H-NMR (Figure 5.7) of 
the ethyl monoester prepared by this method indicated that it was the a-ester 
linkage which remained intact. This was apparent because the splitting pattern 
which is characteristic of the symmetrical CH2 groupings in PC was present. 
Esterification in the a-position would have altered the symmetry of the 
molecule. 
Attention was then turned to the direct esterification of PC. Given that 
there are problems associated with undesirable hydrolysis of PC under 
conditions combining high temperatures and acidity, a mild esterification 
method was sought. Blossey et al. (1973) have reported the use of polymer 
linked A1C13 as a mild catalyst for esterification. This strategy was tested and 
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analysis of monoester filatures from syntheses using this reagent revealed the 
presence of free phosphate, indicating that here again some unwanted 
hydrolysis of PC had occurred. Preparations when analysed using HVE showed 
that high concentrations of PC still remained and was obviously not converted 
to its monoester form by the technique. 
The strategies devised for monoester synthesis highlighted some of the 
problems associated with synthetic work involving PC. One problem which 
proved insoluble was that the polymer linked catalyst needed to be activated by 
solvents such as, benzene or CS2, which are capable of swelling the polymer. 
However an aqueous component could not be avoided in the mixture as PC is 
not soluble in bead activating organic solvents. Problems associated with limited 
solubility or insolubility in most organic solvents and related to unwanted 
hydrolysis from combinations of increased temperature and acidity suggested 
fthe need for more novel ways of producing monoesters of PC if the prodnig 
avenue was to be pursued. The monoesters prepared in this study were not 
trialled using the calcergy model as they were considered to have no greater 
biological potential than the PTEC preparation. 
5.3.5 	General comments 
The synthesis of PTEC has been reported previously (Marcot et al., 
1986) and the authors claimed that administration of the compound to rats 
resulted in dramatic inhibition of urinary stone formation when PTEC was 
administered at a dose level of 2 pg/day. This seems highly unlikely as the PC 
dose needed to achieve 50 % inhibition of calcergic plaque formation was found 
to be 20 mg/kg/day. Further, Sallis et al. (1988) using an infection stone model 
in rats, observed that PC given at 25 mg/kg/day did not elicit a statistically 
significant reduction in bladder stone formation. Assuming that Marcot et al. 
88 
(1986) used rats weighing approximately 200 g, a factor of at least 2000 
difference in the doses required for an effect is apparent. Whilst PTEC, if active 
as a prodrug of PC, might be expected to have increased activity if the plasma 
half life was extended, a factor of at least 2000 seems totally unrealistic. 
During these studies chromatographic separation on either silica or 
alumina did not result in complete isolation of PTEC. However following the 
failure of the compound to act in the prevention of calcinosis, further work on 
its separation was considered unnecessary. 
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSION 
During the last decade, knowledge gained with animal models 
concerning the ability of naturally occurring PC to ameliorate the damaging 
effects of several disease states has been steadily accumulated (Williams and 
Sallis, 1981; Shankar et al., 1986; Tsao et al., 1988; Sallis et al., 1988; Cheung et 
al., 1990). Perhaps the most important and extensive data to date concerning the 
inhibitory power of PC are that which implicates the compound as having a 
potential role in preventing the progression of atherosclerosis. This role, first 
suggested by Williams (1981) one of the early workers in the PC field, if 
eventually expanded clinically may have considerable benefit. Unless 
atherogenesis can be controlled serious medical consequences such as 
myocardial infarction, stroke, gangrene and aneurysm can result (McGill, 1988). 
This has an enormous economic and social burden on the community and the 
cost of this disease to the economy of the United States of America has been 
estimated at 60 billion dollars annually (Comai et aL, 1985). 
Another major area where it may be possible to utilise the potential of 
PC is in urolithiasis. Lithotripsy, a non invasive technique to remove stones, 
once thought to be a panacea, is no longer regarded with such reverence, as 
severe oedema and destruction of kidney tissue can result from the treatment 
(Karlsen et al., 1991). Further, lithotripsy does not address the problem of 
recurring stone formation and so chemical treatment via an inhibitor is an 
excellent option post-surgically. For urinary tract stone formation PC has 
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already proven useful in preventing the formation of mixed stones in rats (Sallis 
et al., 1988). 
• 
To date, studies testing the efficacy of PC have administered the 
compound by intraperitoneal injection. Two aspects of this historical approach 
needed to be addressed. Firstly, information concerning the most effective way 
of delivering PC such that its potential could be maximised needed to be gained, 
and secondly, given that oral delivery of drugs is usually preferred in clinical 
situations, the characteristics of PC absorption from the intestine needed to be 
delineated. In this light the studies presented here were undertaken. It was 
hoped that transport parameters for PC could be delineated, and hence provide 
an invaluable guide to the direction that future biochemical and pharmaceutical 
studies should take. 
The first area to be studied was the determination of the anticalcifying 
ability of PC when administered by different routes. The animal model 
selected was subcutaneous calcergy, described by Doyle et al. (1979) which 
previously had been found suitable for the testing of anticalcifying agents. 
Additional qualification for the model was that subcutaneous calcergy allowed 
comparison of the oral and intraperitoneal administration routes as PC must 
first enter the systemic circulation before passing to the site of calcification. In 
contrast, the dystrophic transplant model which utilised intraperitoneal implants 
and was used by Shankar (1986) would have been unsuitable as in that system 
the calcification target was within the intraperitoneal cavity. Other advantages 
of the calcergy model included the ease with which it could be performed. Apart 
from the initial injection of KMn04, the rats were subjected to minimal trauma 
for the duration of the experiment and complex dietary and/or surgical 
techniques were not required. 
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A detailed dose response curve was constructed to create a model of PC 
effect on calcergy. The calcergic plaques were analysed by weight, calcium and 
phosphate content. The analysis according to weight indicated a non-linear 
reduction in calcergic plaque formation when PC was given by the 
intraperitoneal route. This was mirrored by the reduction in calcium and 
phosphorus content of plaques. The inhibition of calcergic plaques by PC was 
shown to be route dependant and a comparison of the responses to oral and 
intraperitoneal administration indicated that PC was 45 times less effective 
when administered by gavage. 
When PC was administered subcutaneously at a dose level of 50 
mg/kg/day complete inhibition of plaque formation was observed. If future 
studies regarding the ability of subcutaneously administered PC to prevent 
calcergy indicate that low doses of this naturally occurring compound are 
effective, then the possibility of using PC to prevent subcutaneous calcification 
in humans could be considered. Such disorders include calcinosis universalis 
and myositis ossificans progressiva. The chance of success with PC would appear 
high as orally delivered EHDP has been used with beneficial results in the 
treatment of these two conditions (Cram et al., 1971). Not all types of calcinosis 
known might be relieved as there is evidence that EHDP is less useful against 
calcinosis induced by dermatomyositis and scleroderma (Metzger et aL, 1974). If 
a slow release system for PC is a realistic future development, then the potential 
for using the compound in the treatment of pathological calcinosis may be 
further enhanced. 
The reduced bioavailability following oral administration implied by the 
calcergy studies was explored using several techniques which allowed absorption 
from the intestine to be studied more directly. In situ loop experiments revealed 
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a rapid disappearance of PC from the intestinal lumen but the inference of 
complete uptake of PC was not supported by the everted sac experiments. At 
low concentrations of the compound in incubation fluids, no transfer of PC was 
observed. At higher concentrations only limited transfer was detected. However, 
the non physiological conditions of the in vitro studies may have obscured PC 
transport and this idea has been discussed in chapter 3. Perfusion experiments 
in vivo, confirmed that PC was absorbed from the intestine as the compound 
was found in portal vein samples. Again, the studies emphasised the limitations 
of the transport process. 
In terms of a transport mechanism for PC, unlike absorption from renal 
tissue (Wright, 1985), the absorption of carboxylic acids from intestinal tissue 
has been poorly studied in the past. A tricarboxylate carrier has been identified 
in liver mitochondria (Claeys and Azzi, 1989) and renal brush borders (Wright 
et aL, 1980) but a similar transporter has not been isolated in intestinal tissue 
although Browne et aL (1978) have demonstrated empirically that tricarboxylic 
acids are transported by an active mechanism. Wolffram et al. (1990) have 
further characterised tricarboxylic, acid transport through work with intestinal 
brush border membranes of calves. In respect to PC, the compound might be 
capable of undergoing passive transport. However it is generally acknowledged 
that highly charged species have difficulty in crossing biological membranes 
(Schanker, 1971). In relation to the intestine it would be expected that the 
characteristics of the epithelial barrier might result in limited absorption of PC. 
Additional to the transport observations, some evidence of 
biotransformation was obtained. This was seen in the appearance of radioactive 
citrate in the portal vein following perfusion of the intestine with 1,5- 14C-PC 
and supported by data obtained from the everted sac experiments whereby 
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some 25% of the dose initially present was found as citrate after 1 h. However, a 
number of factors were suggestive that hydrolysis of PC to citrate was limited. 
Firstly, a lag time between the beginning of a perfusion and the appearance of 
PC in the portal vein was observed and secondly, citrate transfer via an active 
mechanism (Browne et al., 1978; Wolffram et al., 1990) is probably more rapid 
than PC transfer. Together these factors indicate that it would be false to base 
an estimation of the extent of metabolism on a comparison of the proportions of 
PC and citrate detected in the portal vein. In support of this it was found that, 
unlike the significant increases in citrate concentration noted in the mucosal 
fluid during everted sac experiments, citrate did not accumulate extensively in 
the intestinal lumen during perfusions. Additionally, the return of radioactive 
metabolites from the systemic circulation to the portal circulation could be 
another complication. Certainly the in vitro metabolism observed appeared to 
be rate limited. Whilst the extent of this metabolism would need to be further 
quantified using more extensive experiments that can be better performed 
following the development of an ultrasensitive assay for PC, these studies did 
not indicate that metabolism of PC was a limiting factor in absorption. 
Further experiments which measured the intravenous disappearance of 
PC provided valuable insights into the pharmacological profile of PC. 
Indications of a short half-life for PC in blood combined with poor absorption 
across biological membranes would be additive, resulting in the poor response 
of calcergic plaque reduction to orally administered PC. Jung et al. (1970) 
measured the disappearance of pyrophosphate from plasma following 
intravenous administration in dogs and found that 90% disappeared within 10 
min of giving the intravenous dose. Whilst comparison with the detailed kinetic 
experiments carried out by Jung et al. (1970) is not appropriate, the 
disappearance data for PC indicated a very rapid removal (90% in 1 min). The 
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role of compartmental metabolism and uptake was not explored in these studies 
but it is noted from the studies of Williams (1981) that bone had a high affinity 
for PC (40% uptake of radioactivity within 30 min of an I.V. dose) and that 
general tissue uptake would certainly explain the high rate of PC disappearance. 
Regarding the absorption studies, the gastrointestinal transport of PC 
was confirmed using several methodologies and as suggested by the hydrophilic 
nature of PC this transport appeared limited. Hence the need for a mechanism 
to improve the absorption of PC was apparent. One logical rationale for 
increasing absorption was to develop a lipophilic prodrug of PC. This seemed 
appropriate in the light of success obtained with other compounds. Two notable 
examples of derivatisation being used to improve bioavailability of the parent 
compound are prodrugs of ampicillin and mecillinam (Bundgaard and Hansen, 
1981). 
In this regard the synthesis of simple alkyl esters of PC was examined. 
The triethyl ester of PC proved ineffective in preventing plaque formation when 
tested using the calcergy model. Several reasons for this could be postulated. 
Whilst it was expected that the triester might be well absorbed, confirmation of 
this would require detailed radiolabelling experiments. A slow rate of hydrolysis 
in blood and tissues is another consideration which could have resulted in 
insufficient PC becoming available for an effective response. It is possible that 
only partial hydrolysis occurred which would result in remaining ester linkages 
preventing the compound from having any useful anticalcifying ability (Tew et 
cd., 1980). The positioning of an ester moiety would be critical as it can be 
postulated that a p-monoester, as compared to an a-monoester, would be 
generally less suitable as a prodrug due to a slower hydrolysis rate (Meyer et al., 
1959). 
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Some thought has to be given to the design of future PC prodrugs 
especially in regard to the nature of the epithelial barrier and hydrolytic 
enzymes available for bioconversion. The alkyl chain length of the ester is 
known to influence the release of the parent molecule from the prodrug. 
Kawaguchi et al. (1990) found that hydrolysis of ester prodnigs of zidovudine 
was highly dependant on the length of the acyl chains contained within the 
molecule. The positioning of ester groups can also have relevance regarding the 
absorption rate. For example, Jandacek et al. (1987) found that triglycerides 
were more efficiently absorbed when they contained octyl groups in the 1 and 3 
positions and a long chain fatty acid in the 2 position, as opposed to more 
typical long chain fatty acid triglycerides. 
It is important to note that a monoester of PC will have reduced 
lipophilicity compared to its di- or triester and this compromise between charge 
and lipophilicity will effect the rate of absorption. Regarding this issue, White et 
al. (1980) found that mono or diesterification of dicarboxylic acids was an 
important factor in predicting absorption of drugs. In their example, phthalate 
monoesters were absorbed preferentially to the corresponding diesters. The 
authors claimed that the unstirred water layer probably played an important 
role as the ionic charge on the monoester (pKa = 3.0) would allow them to be 
available for absorption preferentially to the diesters. Consequently, the ideal 
prodrug form of PC may be a monoester esterified on an outer carboxyl group 
with an easily hydrolysable side chain. Problems concerning the eventual 
hydrolysis of ester linkages within PC prodrugs would need to be fully explored 
in vitro to ascertain that future compounds contain bioreversible linkages. 
The ester compounds discussed so far relate to aliphatic derivatisations. 
One of the keys to achieving a useful prodnig configuration of PC may be the 
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use of a specific ester form which can be more easily hydrolysed in vivo. The 
prodrug itself may ideally have a short biological half-life and be subject to 
enzyme action in blood or certain tissues. Nielsen and Bundgaard (1988) have 
used glycolamide esters as prodrugs of carboxylic acids. These compounds have 
short half-lives in blood and are thought to be hydrolysed by cholinesterases. 
Hence if a glycolamide monoester of PC can be developed, this prodrug may 
prove to be a highly effective oral delivery system for PC. 
An additional useful strategy in the development of PC prodrugs might 
be site specific delivery of PC, in a prodmg form, to a relevant tissue (eg. 
kidney) for conversion to active PC. An example of this concept is the use of 
gamma-glutamyl prodrugs which are directed to the kidney and hydrolysed by 
gamma-glutamyltranspeptidase (Stella and Himmelstein, 1980). Another 
possible tool might be the development of lipid drug delivery systems based on 
fat pellets, solid lipid dispersions, microemulsions or liposomes (Eldem and 
Speiser, 1989). Kamperman (1989) has explored this area in regard to 
increasing the biological half-life of PC following parenteral administration with 
some success. However, limited entrapment due to the hydrophilic nature of 
PC, in the carriers trialled has so far proved a restriction. The potential of lipid 
systems would be enhanced if a suitable lipophilic form of PC was available 
synthetically for combining in a lipid vehicle. 
In conclusion, PC was found to have limited absorption from the 
intestine, a factor which severely diminished its efficacy. The studies suggest 
that further work relating• to the biological half-life, tissue distribution, and 
metabolism of PC would be beneficial. However the development of a form of 
PC which is more extensively orally absorbed would facilitate the presentation 
97 
of PC as a drug compound. Given the exciting anticalcifying potential of PC this 
task would seem a priority. 
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